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LIST OF ABBREVIATIONS 
AF: Atrial fibrillation 
CHADS2: Acronym for congestive heart failure, hypertension, age ≥ 75 years, 
diabetes mellitus, previous stroke or TIA (2 points). 
CHA2DS2VASc: Acronym for congestive heart failure, hypertension, age ≥ 75 years 
(2 points), diabetes mellitus, previous stroke or transient ischemic attack (2 points), 
vascular disease, age 65-74 years, and sex class (female). 
CI: Confidence interval 
CT: Computed tomography 
DWMH: Deep white matter hyperintensities 
ECG: Electrocardiogram 
HR: Hazard ratio 
IQR: Interquartile range 
LiLAC: Life Long After Cerebral ischemia 
MRI: Magnetic resonance imaging 
NRI: Net reclassification improvement 
OR: Odds ratio 
PVH: Periventricular white matter hyperintensities 
SD: Standard deviation 
TIA: Transient ischemic attack 
TOAST: Trial of Org 10172 in Acute Stroke Treatment 
WHO: World Health Organization 
V 
ENGLISH SUMMARY 
In Denmark, nearly 11,000 people suffer from stroke every year. Worldwide, stroke 
is the second leading cause of death and the most frequent cause of acquired 
disability. 
About 85% of all strokes are of ischemic origin. The 5-year cumulative risk of 
ischemic stroke recurrence after an incident ischemic stroke reaches 32% in some 
studies. Therefore, initiatives to prevent stroke recurrence are an essential part of the 
medical therapy following ischemic stroke. The risk of ischemic stroke recurrence is 
not uniformly distributed among patients. Some patients have a risk considerably 
above the average risk of recurrence, and some patients have a risk considerably 
below the average risk of recurrence. At present, all patients except those with atrial 
fibrillation receive the same kind of medical therapy after ischemic stroke. However, 
in a future perspective, valid risk stratification tools may help clinicians provide a 
more individualized treatment that strikes an optimal balance between risks and 
benefits. 
The CHA2DS2VASc score is a risk score scheme developed for stroke and 
thromboembolic risk stratification in patients with atrial fibrillation. This score 
system has found widespread application among clinicians and is now deployed 
worldwide to guide the selection of atrial fibrillation patients for oral anticoagulation. 
Besides patients with atrial fibrillation, the CHA2DS2VASc score has proved useful 
for stroke and thromboembolic risk stratification in various other groups of patients; 
however, the validity of the CHA2DS2VASc score has only been sparsely 
investigated in patients with ischemic stroke and no atrial fibrillation. 
The aim of study 1 was to investigate how the CHA2DS2VASc score predicts the risk 
of ischemic stroke recurrence in a nationwide cohort of patients with incident 
ischemic stroke and no atrial fibrillation, and to compare the CHA2DS2VASc score 
with the more specific Essen Stroke Risk Score. We found an association between an 
increasing CHA2DS2VASc score and Essen Stroke Risk Score and the risk of 
ischemic stroke recurrence. The discriminatory performance of both scores was 
modest with C-statistics about 0.55. 
To investigate the predictive value of radiological variables of cerebral small vessel 
disease and the risk of ischemic stroke recurrence, and to investigate the potential of 
these variables for enhancing the performance of the CHA2DS2VASc score and the 
Essen Stroke Risk Score, we identified a local cohort of patients with incident 
ischemic stroke, no atrial fibrillation, and an available brain MRI scan. On the MRI 
scans, we rated the severity of white matter hyperintensities and we counted the 
number of silent lacunes. 
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In Study 2, we investigated the association between white matter hyperintensities and 
the risk of ischemic stroke recurrence in patients without atrial fibrillation. 
Furthermore, we investigated the potential for enhancing the performance of the 
CHA2DS2VASc score and the Essen Stroke Risk Score with information on white 
matter hyperintensities. We found a statistically significant association between the 
severity of white matter hyperintensities and the risk of ischemic stroke recurrence. 
By adding one point for moderate-to-severe white matter hyperintensities to the 
CHA2DS2VASc score and the Essen Stroke Risk Score, we found a statistically 
significant increase in the C-statistic of both scores. The score based on white matter 
hyperintensities alone had the numerically highest C-statistic, though this was not 
significantly better than the C-statistic of the clinical scores. 
In Study 3, we investigated the association between silent lacunes and the risk of 
ischemic stroke recurrence. We found that patients with multiple (two or more) silent 
lacunes had an increased risk of a recurrent ischemic stroke compared with patients 
with no silent lacunes. The addition of one point for multiple silent lacunes did not 
enhance the discriminatory performance of the CHA2DS2VASc score and the Essen 
Stroke Risk Score in ischemic stroke recurrence prediction. 
To summarize, we found an association between an increasing CHA2DS2VASc score 
and Essen Stroke Risk Score and the risk of recurrent ischemic stroke in patients with 
incident ischemic stroke and no atrial fibrillation. Both of the investigated risk scores 
showed modest discriminatory performance, and routine clinical application in stroke 
recurrence prediction is not recommended. For the first time, we show that the 
discriminatory performance of the CHA2DS2VASc score and the Essen Stroke Risk 
Score can be enhanced by adding one point for moderate-to-severe white matter 
hyperintensities, and that white matter hyperintensities alone show better, though 
insignificant, discriminatory performance than the clinical scores in the prediction of 
ischemic stroke recurrence. Future studies should focus on the development of stroke 
risk scores based on neuroimaging variables like white matter hyperintensities, 
possibly in combination with clinical variables. 
 
  
VII 
DANSK RESUME 
Apopleksi rammer årligt næsten 11.000 danskere. På verdensplan er apopleksi den 
næsthyppigste årsag til død og den hyppigste årsag til erhvervet handicap. 
Iskæmisk apopleksi udgør cirka 85% af alle tilfælde af apopleksi. Den kumulerede 
5-årsrisiko for ny apopleksi efter den første iskæmiske apopleksi angives i visse 
studier at være helt op til 32%. Tiltag med henblik på forebyggelse af ny apopleksi 
er derfor en vigtig del af den efterfølgende medicinske behandling. Risikoen for 
recidiv varierer dog mellem patienter, således at risikoen for nogle grupper af 
patienter er væsentligt højere og for andre grupper væsentligt lavere end den 
gennemsnitlige risiko. På nuværende tidspunkt er den medicinske behandling i vid 
udstrækning den samme for alle patienter med iskæmisk apopleksi uden atrieflimmer, 
men på sigt kunne valide værktøjer til risikostratifikation af patienter med iskæmisk 
apopleksi uden atrieflimmer bidrage til en mere individualiseret behandling med 
optimal balance mellem risici og fordele for den enkelte. 
CHA2DS2VASc-scoren er en risikoscore udviklet med henblik på stratifikation af den 
individuelle risiko for apopleksi og systemisk tromboembolisme hos patienter med 
atrieflimmer. CHA2DS2VASc-scoren har opnået stor udbredelse og anvendes nu som 
hjælp til udvælgelse af patienter til oral antikoagulation over store dele af verden. 
Desuden har den vist sig brugbar til risikostratifikation i et bredt udsnit af andre 
patientkategorier, men har kun i begrænset omfang været undersøgt hos patienter 
med iskæmisk apopleksi uden atrieflimmer. 
Formålet med studie 1 var at undersøge anvendeligheden af CHA2DS2VASc-scoren 
til prædiktion af risikoen for recidiv af apopleksi i en landsdækkende kohorte af 
patienter med førstegangs iskæmisk apopleksi uden atrieflimmer, og sammenligne 
CHA2DS2VASc-scoren med Essen Stroke Risk Score. Vi fandt en sammenhæng 
mellem stigende CHA2DS2VASc-score og Essen Stroke Risk Score og risikoen for 
recidiv af iskæmisk apopleksi. Diskriminationsevnen af begge scores i forhold til ny 
iskæmisk apopleksi var lav med C-statistics omkring 0.55. 
Med henblik på at undersøge den prædiktive værdi af radiologiske variable i forhold 
til ny apopleksi og disses værdi i forhold til at optimere CHA2DS2VASc-scoren 
identificerede vi en lokal kohorte af patienter med førstegangs iskæmisk apopleksi 
uden atrieflimmer, som havde undergået MR scanning af hjernen. På MR 
scanningerne beskrev vi sværhedsgraden af småkarssygdom i form af white matter 
hyperintensities og klinisk stumme lakuner. 
I studie 2 undersøgte vi sammenhængen mellem white matter hyperintensities på MR 
og risikoen for ny apopleksi samt hvorvidt tillæg af ét point til CHA2DS2VASc-
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scoren og Essen Stroke Risk Score for moderate til svære white matter 
hyperintensities kunne øge diskriminationsevnen af disse kliniske scores. Vi fandt en 
stigende risiko for recidiv af iskæmisk apopleksi med stigende sværhedsgrad af white 
matter hyperintensities. Ved at lægge ét point til CHA2DS2VASc scoren og Essen 
Stroke Risk Score for moderate til svære white matter hyperintensities fandt vi en 
statistisk signifikant øget diskriminationsevne af begge scores, vurderet ved C-
statistics. Scoren baseret udelukkende på white matter hyperintensities havde den 
bedste diskriminationsevne af alle scores, omend den dog ikke var statistisk 
signifikant bedre end de kliniske scores. 
I studie 3 undersøgte vi sammenhængen mellem klinisk stumme cerebrale lakuner og 
risikoen for recidiv af iskæmisk apopleksi. Vi fandt, at patienter med multiple (to 
eller flere) stumme lakuner på MR havde en øget risiko for recidiv af iskæmisk 
apopleksi sammenlignet med patienter uden stumme lakuner. Tillæg af ét point for 
tilstedeværelse af multiple stumme lakuner på MR førte ikke til bedre 
diskriminationsevne af CHA2DS2VASc scoren og Essen Stroke Risk Score. 
Sammenfattende fandt vi en sammenhæng mellem stigende CHA2DS2VASc score og 
Essen Stroke Risk Score og øget risiko for recidiv af iskæmisk apopleksi hos patienter 
med førstegangs iskæmisk apopleksi uden atrieflimmer. Begge scores havde dog en 
lav diskriminationsevne, og klinisk anvendelse af de to scores i denne sammenhæng 
kan ikke anbefales. For første gang har vi vist, at diskriminationsevnen af 
CHA2DS2VASc-scoren og Essen Stroke Risk Score kan øges ved at tillægge point 
for white matter hyperintensities, og at white matter hyperintensities alene har bedre, 
men dog ikke signifikant bedre, diskriminationsevne end CHA2DS2VASc scoren og 
Essen Stroke Risk Score i prædiktionen af recidiv af iskæmisk apopleksi. Fremtidige 
studier bør fokusere på at udvikle anvendeligheden af scores baseret på white matter 
hyperintensities, eventuelt i kombination med kliniske variable. 
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CHAPTER 1. INTRODUCTION 
The themes of this dissertation are ischemic stroke and risk stratification in non-atrial 
fibrillation (AF) ischemic stroke patients. The central topic is the assessment of the 
risk of recurrent ischemic stroke. This topic is explored through three sub-topics: 1) 
Evaluation of the performance of existing risk score schemes, mainly the 
CHA2DS2VASc (congestive heart failure, hypertension, age ≥ 75 years, diabetes 
mellitus, previous stroke or TIA, vascular disease, age 65-74 years, and sex class 
(female)) score1, in the prediction of recurrent ischemic stroke. 2) The association of 
radiological signs of cerebral small vessel disease and the risk of recurrent ischemic 
stroke. 3) The potential of combining existing clinical risk score schemes with 
information on small vessel disease to enhance the performance of the existing score 
schemes in stroke recurrence risk prediction. As an introduction to the following 
chapters on the specific studies, I present some basic aspects of stroke and cerebral 
small vessel disease, and introduce the CHA2DS2VASc score. 
1.1. STROKE 
Stroke is defined by the World Health Organization (WHO) as “rapidly developed 
clinical signs of focal (or global) disturbance of cerebral function, lasting more than 
24 hours or leading to death, with no apparent cause other than of vascular origin”.2 
This definition covers very different, common diseases of vascular origin: brain 
infarcts, intracerebral hemorrhages, and subarachnoid hemorrhages, besides some 
more rare conditions.2 Even though this definition of stroke, which was introduced in 
1970, is obsolete mainly because of the advent of modern neuroimaging techniques, 
it still very well captures the clinical appearance of a stroke: sudden symptoms that 
without warning deprives the victim of his physical and/or mental independency, or 
even life. The consequences are enormous for the individual and for the society. 
A recent attempt to revise the stroke definition refers to ischemic stroke as “an 
episode of neurological dysfunction with evidence of central nervous system 
infarction.”3 The evidence of infarction will generally be based on neuroimaging. The 
same document gives an analogous definition of hemorrhagic stroke: “neurological 
dysfunction with evidence of intracerebral hemorrhage.” In Danish, the word 
“apopleksi” usually covers ischemic and hemorrhagic strokes together, but does not 
include subarachnoid hemorrhage. In the present dissertation, I use “stroke” as a 
collective term to cover ischemic and hemorrhagic strokes. Where appropriate, stroke 
will be categorized as ischemic or hemorrhagic.  
The definition of transient ischemic attack (TIA) is also under revision. The classic 
definition formulated in 19754 did not take imaging findings into account. In the 
current Danish guidelines, TIA is diagnosed in case of symptoms lasting less than 24 
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hours and no evidence of CNS infarction.5 Otherwise, the attack should be considered 
an instance of (ischemic) stroke. 
Epidemiology 
Stroke is a very common disease. Worldwide, stroke is the second leading cause of 
death and the most frequent cause of acquired disability.6 Over the last four decades, 
the incidence rate of stroke has decreased in the high-income countries, whereas the 
opposite trend is seen in the low- to middle-income countries.7 In Denmark in 2014, 
almost 11,000 cases of stroke occurred in the population aged >18 years; of these, 
approximately 85% were of ischemic origin. In addition, about 4,200 cases of TIA 
occurred. The overall incidence rate of stroke was 2.4 per 1,000 person-years, and 
the overall incidence rate has been slightly decreasing during the past decade.8 The 
thirty-day mortality was 7% in ischemic stroke and 26% in hemorrhagic stroke.9 In 
Denmark, an estimated 30,000-40,000 people live with disabilities after a stroke.5 
Ischemic Stroke 
Ischemic stroke is a very heterogeneous disease. Its causes are many, counting age-
related conditions, heart diseases, genetic causes, inflammatory and immunologic 
diseases, among many others. A few causes are very common, whereas the majority 
of causes are relatively rare. In every patient, an individualized diagnostic workup 
should be instituted to identify the underlying cause of the stroke. Correct 
identification of the cause has important implications for treatment and prognosis.5,10 
Ischemic stroke can be subtyped according to various classification systems.10 The 
most widely applied classification system is The Trial of Org 10172 in Acute Stroke 
Treatment (TOAST) classification, introduced in 1993.11 This system is an 
etiologically based classification system with five categories: large-artery 
atherosclerosis, cardioembolism, small vessel occlusion, stroke of other determined 
cause, and stroke of undetermined cause. This classification system is far from 
perfect, and the frequency of the different categories may vary with the persistence 
displayed during diagnostic workup.10 Despite its shortcomings, the TOAST 
classification contributes to an understanding of the heterogeneity of stroke 
pathophysiology and can be used for comparison of the relative frequencies of the 
defined causes. 
In recent European studies of the distribution of stroke subtypes according to the 
TOAST classification, 11-36% were due to large-artery atherosclerosis, 24-31% were 
due to cardioembolism, 23-31% were caused by small vessel occlusion, and 2-26% 
were of undetermined or other causes.12–15 AF is quantitatively the most important 
cause of cardioembolic stroke.16 
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Management of Ischemic Stroke 
The acute management of stroke has evolved dramatically over the past few years. 
Intravenous thrombolytic therapy of acute stroke with alteplase (recombinant tissue-
type plasminogen activator, tPA)17,18 was approved in Denmark in 2003; and in 2015, 
mechanical thrombectomy became standard care for patients with large-vessel 
occlusions.19–21 Unfortunately, only 15% of the stroke patients are offered these new 
treatments,9 primarily due to time delays in hospitalization and individual 
contraindications to the interventions. Hence, despite these landmarks in acute stroke 
care, secondary prevention remains the cornerstone in the treatment of the majority 
of ischemic stroke patients. Secondary prevention consists of medications, surgical 
interventions, management of comorbidities, and lifestyle modifications.22 
The primary goal of secondary prevention is to prevent stroke recurrence and other 
related diseases. In AF patients, oral anticoagulant therapy has proved effective in 
the prevention of stroke and thromboembolism.23–26 Treatment decisions are guided 
by risk stratification according to the CHA2DS2VASc score, and this score is now an 
integrated part of clinical management of AF patients.27,28 In non-AF stroke patients, 
no single risk score scheme has gained broad application, and only a few of the 
existing score schemes have been developed specifically for patients with non-
cardioembolic stroke.29,30 Broadly speaking, secondary preventive medical treatment 
in non-AF stroke patients is the same irrespective of the underlying cause and the 
patient’s individual characteristics (apart from some uncommon causes of stroke).5,31 
Validation of risk assessment tools for this group of patients may therefore be the 
first step towards a differentiated and individualized treatment strategy that may lead 
to an optimized risk-benefit ratio for all patients. 
1.2. CEREBRAL SMALL VESSEL DISEASE 
Cerebral small vessel disease refers to a group of diseases affecting the small vessels 
of the brain. The quantitatively most important etiology of small vessel disease is 
related to age and vascular risk factors. In addition, amyloid angiopathy is relatively 
common. Other more rare causes are genetic diseases and iatrogenic conditions, for 
example post-radiation small vessel disease.32 Though the disorders of the vessels 
and the resulting parenchymal changes are pathologically defined entities strictly 
speaking, and thereby only very rarely accessible for direct study, neuroimaging 
characteristics are established in vivo surrogate markers of small vessel disease.33  
The conventional magnetic resonance imaging (MRI) markers of cerebral small 
vessel disease are white matter hyperintensities, lacunes, cerebral microbleeds, and 
enlarged perivascular spaces.34–37 Leukoaraiosis and age-related cerebral white 
matter changes are synonymous with white matter hyperintensities.38 In the existing 
literature, a predominance of studies focus on white matter hyperintensities and 
lacunes because these changes are visible on computed tomography (CT). However, 
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with the wider access to MRI, more attention is now being paid to microbleeds and 
enlarged perivascular spaces. 
Prevalence 
Beyond doubt, the prevalence of cerebral small vessel disease is age-dependent. In 
the population-based Rotterdam Scan Study, the prevalence of moderate-to-severe 
white matter hyperintensities was 11% in those aged 65-69 years and rose to 54% in 
those aged 80-84 years.39 In the same study, the prevalence of silent cerebral infarcts 
(of which 95% were lacunes) was 8% in those aged 60-64 years and 35% in the age 
group above 85 years.40 The prevalence of cerebral microbleeds was 17.8% in the 
group aged 60-69 years and 38.3% in those above 80 years.41 
In the review of studies on radiologically assessed cerebral small vessel disease, it is 
important to notice that numerous rating scales exist for the assessment of white 
matter hyperintensities.42 These scales may differ with respect to the areas of the brain 
included in the rating. Some are visually based, while others rely on computerized 
volumetric measurements.43 Similarly, differences in imaging protocols, equipment, 
and definitions may hamper direct comparison between studies of prevalence and 
significance of the imaging parameters described above. 
Clinical Consequences 
Cerebral small vessel disease is associated with a number of serious clinical 
symptoms: cognitive decline, dementia, gait disturbances, and urinary 
incontinence.44,45 Although these symptoms are generally accepted consequences of 
small vessel disease, the correlation between the severity of the radiological changes 
and the clinical disability is more ambiguous. Widespread small vessel disease may 
apparently be clinically silent and, on the other hand, patients with obvious clinical 
symptoms consistent with cerebral small vessel disease may harbor only mild 
changes on neuroimaging.44,45 Besides the aforementioned symptoms, small vessel 
disease has also been linked to an increased risk of recurrent ischemic stroke. 
Neuroimaging signs of small vessel disease may therefore have potential as 
predictors of stroke, in isolation or in the combination with existing risk scores such 
as the CHA2DS2VASc score. 
1.3. THE CHA2DS2VASC SCORE 
Risk prediction is the estimation of a person’s risk or probability of experiencing a 
certain event over a specific time. The event could be a disease, death, or effect of a 
treatment. Risk stratification is an approach that divides patients into risk groups 
according to their individual risk, and stratification may be accomplished using risk-
score schemes, for instance the CHA2DS2VASc score. Hence, risk stratification is a 
tool to predict the prognosis of the patient.46,47  
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The use of risk stratification for prognostic purposes may serve several additional 
purposes. First, the prognosis is of particular interest to the patient and is an important 
element in the counseling of the patient and the relatives. Documentation of a 
particular high risk may help motivate the patient to accept risk-factor-modifying 
lifestyle behavior. Furthermore, risk stratification may guide treatment decisions and 
can be used in research to select patients for a study or to allocate patients to different 
treatments.46 
Risk stratification can be based on a variety of different predictors or variables. 
Clinical variables are probably the most commonly included predictors in risk-score 
schemes, and the CHA2DS2VASc score is an example of an exclusively clinically 
based risk score. The CHA2DS2VASc score is a refinement of the simpler CHADS2 
(heart failure, hypertension, age ≥ 75 years, diabetes mellitus, previous stroke or TIA) 
score48 and it was developed specifically for the stratification of stroke and 
thromboembolic risk within 1 year in AF patients. Since its introduction, the 
CHA2DS2VASc score has been validated in various cohorts49,50 and has proven 
applicable for stroke risk prediction in various groups of patients without AF, 
including patients with ischemic stroke,51 coronary heart disease,52 patients 
undergoing coronary artery bypass,53,54 and patients with congestive heart failure.55 
In addition, the CHA2DS2VASc score may predict the risk of new-onset AF56 as well 
as the risk of stroke and thromboembolism in the general population.57 Recently, the 
CHA2DS2VASc score showed promise of enhanced performance when combined 
with information on chronic kidney disease.58 Hence, the CHA2DS2VASc score 
seems to be applicable in various different patient categories and may have the 
potential to become an even better predictor if combined with selected new variables.  
Summary 
Ischemic stroke is a common disease with great impact on the individual and on 
society. Only few risk stratification studies have focused specifically on patients with 
non-AF related ischemic stroke. Cerebral small vessel disease affects the small, deep 
vessels of the brain and can be visualized in vivo on standard neuroimaging protocols. 
Neuroimaging signs of cerebral small vessel disease have been associated with an 
increased risk of recurrent ischemic stroke and these signs may serve as predictors of 
stroke risk. The CHA2DS2VASc score is a clinically based risk score scheme with a 
promising potential to improve risk stratification in various patient categories and to 
become an even better predictor if combined with other, new predictors. 
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CHAPTER 2. AIMS 
The aims of this dissertation are: 
1. To evaluate how the CHA2DS2VASc score predicts ischemic stroke 
recurrence, death, and cardiovascular events in a nationwide cohort of non-
AF patients with incident ischemic stroke and to compare its performance 
in this respect with that of the more specific Essen Stroke Risk Score. 
 
2. To investigate the association of white matter hyperintensities with the risk 
of ischemic stroke recurrence, death, and cardiovascular events, and to 
investigate whether information on white matter hyperintensities can 
enhance the predictive performance of the CHA2DS2VASc score and the 
Essen Stroke Risk Score. 
 
3. To investigate the association of silent lacunes with the risk of ischemic 
stroke recurrence, death, and cardiovascular events, and to investigate 
whether information on silent lacunes can enhance the predictive 
performance of the CHA2DS2VASc score and the Essen Stroke Risk Score. 
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CHAPTER 3. CLINICAL RISK SCORES 
AND RECURRENT ISCHEMIC STROKE 
As outlined in Chapter 1, risk stratification in AF patients and in stroke patients with 
AF is an integrated part of clinical practice. The individual risk assessment in stroke 
patients without AF has been studied much less intensively although this group 
constitutes more than three fourths of all ischemic stroke patients. Attempts to expand 
knowledge in this important area are of major clinical interest and may benefit 
patients in the future. 
Study 1 aimed to evaluate the performance of the CHA2DS2VASc score in the 
prediction of recurrent ischemic stroke, death, and cardiovascular events in a cohort 
of non-AF patients with incident ischemic stroke. We compared the performance of 
the CHA2DS2VASc score with that of the Essen Stroke Risk Score.59,60 The latter is 
a point-based risk score scheme developed specifically for prediction of recurrent 
ischemic stroke within 1 year from the index stroke. The concept of this model is 
very similar to that of the CHA2DS2VASc score, even if they differ slightly in the 
included variables (The Essen Stroke Risk Score is shown in Appendix A). 
3.1. RISK OF RECURRENT ISCHEMIC STROKE 
The cumulative risk of stroke recurrence varies among cohorts.61 Studies reporting 
on the cumulative risk of stroke recurrence differ in their inclusion criteria: some 
included only ischemic stroke, whereas others included all types of stroke.61 In a 
meta-analysis, Mohan et al. found no significant differences in recurrence risk 
between studies reporting on ischemic stroke only versus those reporting on all types 
of stroke.61 In the following, I focus on clinically relevant time perspectives and 
include studies on all types of stroke.  
In the derivation cohort of the Recurrence Risk Estimator at 90 days (RRE-90)62 and 
in the Oxford Vascular Study63, the cumulative risk of recurrent ischemic stroke 
varied from 2.6% to 11.5% at 7 days and from 6.0% to 18.5% at 90 days. The 
cumulative risk of stroke recurrence at 1 year varied from 7.1% in the South London 
Stroke Registry64 to 16.0% in the Perth Community Stroke Study.65 Corresponding 
values at 5 years in the same two cohorts were 16.2% and 32.0%, respectively, and 
at 10 years 24.5% and 43.0%, respectively. 
In a meta-analysis, subdivision according to the TOAST classification showed that 
the risk of ischemic stroke recurrence was highest for large-artery atherosclerosis and 
lowest for small vessel stroke: 19.2% versus 3.4% at 3 months.66 The recurrence risk 
at 3 month after cardioembolic stroke was 11.9%. 
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In The South London Stroke Register,67 the incidence rate of stroke recurrence among 
patients where ischemic stroke was the index event was 7.8% during the first year of 
follow-up, whereas the incidence rate was only 2.5% during the fifth year of follow-
up. Similar results were found in the Life Long After Cerebral ischemia (LiLAC) 
study cohort.68 In a Finnish study of young stroke patients (15-49 years)69, the 
incidence rate of stroke recurrence was 3.0% during the first year, whereas the yearly 
recurrence rate declined to about 2% the following years. 
Mohan et al. performed a meta-analysis of 13 studies reporting on the cumulative risk 
of stroke recurrence.61 The included studies covered a period of 50 years. In their 
analyses, they observed a trend of decreasing stroke recurrence risk in the more recent 
studies. This is in accordance with a Swedish study that reported a hazard ratio of 
stroke recurrence of 0.64 (95% CI 0.52-0.78) for patients included in the cohort in 
2004-2008 versus those included in 1995-1998.70 
In conclusion, the risk of stroke recurrence is considerable. During the first 5 years, 
the cumulative risk of recurrence varies between 16% and 32%,64,65 and large-artery 
atherosclerosis-related stroke may carry the highest risk of recurrence. The rate of 
recurrence is highest in the period immediately after the stroke and declines in the 
years following the index event. Overall, the risk of stroke recurrence seems to have 
decreased during the past 20 years. 
3.2. RISK SCORE SCHEMES IN ISCHEMIC STROKE 
Existing Models 
There are several risk score schemes and models for predicting ischemic stroke. Most 
famous is probably the Framingham risk score which estimates the risk of stroke 
within 10 years in the general population.71 However, the Framingham risk score was 
developed for estimating the risk of incident stroke in the general population. Yet, 
from the neurologist’s perspective, the risk of recurrent stroke is most often the 
relevant question. 
The table in Appendix B gives an overview of various multivariable risk prediction 
models derived from TIA and stroke cohorts and aimed for estimating the risk of a 
recurrent ischemic stroke or, in the TIA patients, the risk of a subsequent stroke. The 
table includes only models with specific assessment of stroke recurrence risk. The 
table was modified from Thompson et al.72 and has been extended with models not 
fulfilling their inclusion criteria as well as models derived from TIA cohorts. 
The models vary in terms of the number of included variables and the complexity of 
these variables and, thereby, in the complexity of the different model. The most 
frequently included variables are age, history of TIA or stroke, hypertension, and 
diabetes.72 Some models included variables based on advanced neuroimaging or 
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electrocardiographic (ECG) characteristics. Besides varying in terms of the included 
variables and overall complexity, the models also vary considerably in their time 
perspective; some estimate stroke risk within 2 days73, whereas others estimate stroke 
recurrence risk up to 10 years after the index event.68 
Some of the models are point-based, whereas others are based on regression 
equations. In point-based models, one or more points are added for each variable 
present. A major advantages of these models are the simplicity of calculating the 
individual score and that the ability to tabulate the associated risk in a simple table. 
The most significant disadvantage is that information is lost when a regression 
coefficient is reduced to a binary variable (present/not present).47 In the models with 
more advanced regression equations, a computer is needed to calculate the risk; 
however, today this can easily be accomplished with a web-based model or a mobile 
app.72 
Evaluation and Comparison of Prediction Models 
Prediction models must be evaluated to quantify and document how well they predict 
the outcome. In point-based models such as the CHA2DS2VASc score and the Essen 
Stroke Risk Score, tabulation of the observed risk or incidence rates stratified on the 
score is a simple way to obtain an overview of the applicability of the prediction 
model. However, more thorough methods of evaluation are necessary, for example 
to determine the discriminative performance. The discriminative performance of a 
prediction model is its ability to discriminate between those with and those without 
the outcome of interest. A commonly applied statistical measure of discrimination is 
the C-statistic. For binary outcomes, the C-statistic is calculated as the area under the 
receiver operating characteristics (ROC) curve.47 The C-statistic of a model is the 
probability that an individual with the event of interest is assigned a higher predicted 
probability than an individual without the event.74 A C-statistic of 1.0 indicates 
perfect discrimination, whereas a C-statistic of 0.5 indicates that the model is no 
better than chance in predicting the outcome.75 The calibration of a prediction model 
is an assessment of the agreement between the predicted and the observed risk.75 Most 
studies report measures of discrimination, whereas measures of calibration are more 
sporadically reported. In the studies of this dissertation, we applied the C-statistic as 
the primary measure of model performance. Calibration is mainly relevant in 
validation studies, and we did not assess calibration in our studies as, per definition, 
the predicted risk was identical to the observed risk. A prediction model is developed 
from a derivation cohort in which the variables are selected. The model should 
subsequently be evaluated in other cohorts to prove its external validity.76 
Thompson et al.72 performed a meta-analysis of validation studies in stroke cohorts 
and they were able to report pooled C-statistics for the Essen Stroke Risk Score and 
the Stroke Prognosis Instrument-II. The pooled C-statistics were 0.60 (95% 
confidence interval (CI) 0.59-0.62) and 0.62 (95% CI 0.60-0.64), respectively. 
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Among all included models in the validation studies, C-statistics varied between 0.50 
and 0.75. Of the 27 C-statistic values reported, only two were above 0.70. Both of 
these were in studies of the Recurrence Risk Estimator at 90 days (RRE-90).77 In 
comparison, the CHA2DS2VASc score (on the composite thromboembolic endpoint) 
had C-statistics of 0.61 (95% CI 0.51-0.70) in the derivation cohort1 and 0.66 (95% 
CI 0.63-0.69) and 0.67 (95% CI 0.67-0.68), respectively, in two subsequent 
validation studies.49,50  
3.3. STUDY 1 
Results 
Study 1 was a register-based cohort study on patients with incident ischemic stroke 
and no AF. Patients who suffered incident ischemic stroke in the period 2003-2012 
were identified in the Danish Stroke Registry, and data were linked with information 
from the Danish National Patient Registry, The National Prescription Registry, and 
The Danish Civil Registration System. The outcomes were recurrent ischemic stroke, 
death, and cardiovascular events. 
The study comprised 42,182 patients with a median age of 70.1 (interquartile range 
(IQR) 19.3) years. Based on the information in the registries, we calculated the 
CHA2DS2VASc score and the Essen Stroke Risk Score. Patients were followed up 
until ischemic stroke recurrence, or death, whichever came first. 
The cumulative risk and the incidence rates of all three outcomes increased with 
increasing values of the risk scores at both 1 and 5 years. The figures in Appendix C 
Table 1. C-statistics for the CHA2DS2VASc score and the Essen Stroke Risk 
Score. 
Endpoint     
CHA2DS2VASc 
score 
  
Essen Stroke Risk 
Score 
Recurrent ischemic 
stroke 
1-year 
 
0.52 (0.51-0.53)  0.54 (0.53-0.55) 
 5-year  0.54 (0.53-0.55)  0.56 (0.55-0.57) 
Death 1-year  0.68 (0.67-0.68)  0.65 (0.64-0.66) 
 5-year  0.68 (0.68-0.69)  0.66 (0.66-0.67) 
Cardiovascular 
events 
1-year  0.53 (0.52-0.54)  0.55 (0.54-0.56) 
5-year   0.55 (0.54-0.56)   0.57 (0.57-0.58) 
Data are C-statistics (95% CI). 
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show the stratified cumulative risk of recurrent ischemic stroke. Similarly, the Cox 
proportional hazard ratios rose with increasing values of the risk scores. The C-
statistics of the discriminative performance of the scores are shown in Table 1. The 
1-year negative predictive value for recurrent ischemic stroke for a CHA2DS2VASc 
score of 2 was 0.94 (95% CI 0.94-0.95), and the corresponding value for an Essen 
Stroke Risk Score of 0 was 0.95 (95% CI 0.94-0.96). 
Study-Specific Methodological Considerations on Study 1 
In the study cohort of Study 1, 25.3% of the patients died during follow-up. Death 
precludes the occurrence of the event of interest; in this case recurrent ischemic stroke 
and cardiovascular events. Therefore, death is considered to be a competing risk, and 
this should be taken into account in the calculation of the risk of the outcome of 
interest.78 In the conventional Kaplan-Meier approach, censoring is non-informative. 
However, death is tantamount to informative censoring: those patients who die are 
no longer at risk.79 The significance of competing risks depends on the duration of 
follow-up and the frailty of the study population. Short periods of follow-up and low 
mortality in a study cohort decrease the extent to which competing risks affect the 
estimates. Without competing risks, there is a one-to-one correspondence between 
the rate and the risk for the outcome of interest. In case of competing risks, this one-
to-one relation between the cause-specific (for the outcome of interest) rate and the 
risk no longer exists.80 The result is a biased estimate of the cumulative incidence 
based on the Kaplan-Meier estimator. Another consequence is that the effect of the 
covariates may differ in the cause-specific hazard function and the cumulative 
incidence function.79–81 Thus, covariates or predictors selected on the basis of the Cox 
proportional hazards do not necessarily contribute to the cumulative incidence with 
the same weight as observed in the regression model. Based on these considerations, 
we calculated the cumulative risk and the C-statistic, taking into account the 
competing risk of death. 
We identified the study cohort in the Danish Stroke Registry although the cohort 
could also have been identified in the Danish National Registry of Patients. A recent 
study investigated and compared the validity of the stroke diagnoses of these two 
registries.82 The sensitivity of the stroke diagnoses in the Danish Stroke Registry was 
91-97%, and the positive predictive value was 90%. In the Danish National Registry 
of Patients, the sensitivity was 58-79% and the positive predictive value was 79%. 
We drew samples of patients with incident ischemic stroke and no AF in the period 
2003-2012 from both registries. The sample from the Danish National Registry of 
Patients comprised about 62,000 patients, whereas the sample from the Danish Stroke 
Registry comprised about 42,000 patients. In the light of these numbers and the above 
cited results on sensitivity and positive predictive values, we chose the Danish Stroke 
Registry as the source of the study population.  
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Discussion 
As seen from the table in Appendix B, the factors included in the CHA2DS2VASc 
score are not very different from the factors in many of the stroke-specific models. 
Hence, from a theoretic point of view, the CHA2DS2VASc score is likely to be 
predictive of the risk of ischemic stroke recurrence among stroke patients. 
From a clinical point of view, the absolute risk of the outcome will usually be the 
most relevant measure to guide treatment decisions. The 1-year cumulative risks of 
stroke recurrence were about 2.5% versus 4.1% for a CHA2DS2VASc score of 2 
versus ≥7, respectively (figures in Appendix C). While the Cox proportional hazard 
analyses showed that a CHA2DS2VASc score ≥7 was associated with a statistically 
significantly higher relative risk of ischemic stroke recurrence, it may be questioned 
whether this difference is also of clinical significance. Compared with the 1-year 
cumulative risks of death ranging from about 2.5% to 22% for a CHA2DS2VASc 
score of 2 versus ≥7, respectively, the differences in stroke recurrence risk are only 
minor. The differences in the 5-year cumulative risks were somewhat larger: the risk 
of recurrent ischemic stroke ranged from about 7% to 10%. In comparison, in a 
Swedish registry study, the annual stroke rate in non-anticoagulated AF patients 
varied from 0.2% to 12.2% for a CHA2DS2VASc score of 0 versus 9.50 In the light of 
these numbers, the performance and the clinical utility of the CHA2DS2VASc score 
was not very convincing in our cohort.  
The Essen Stroke Risk Score was a better tool for determining the risk of recurrent 
ischemic stroke. The 1-year cumulative risk ranged from about 2% to 4% whereas 
the 5-year risk ranged from about 5% to 11% for a score of 0 versus a score of ≥5, 
respectively; and the corresponding hazard ratios for a score of ≥5 were higher: 2.30 
(95% CI 1.64-3.22) (1-year) and 2.81 (95% CI 2.22-3.54) (5-year). With high-risk 
patients having more than twice the risk of stroke recurrence, the results of the Essen 
Stroke Risk Score are of greater clinical relevance. However, it is debatable whether 
we identified a group that had a particularly high risk. Compared with the stroke risk 
in the AF patients,50 the baseline stroke risk in our patients is considerable. In other 
words, all stroke patients are high-risk patients, at least when stratified by these two 
clinical scores. 
As expected, the incidence rates of cardiovascular events were higher than the 
incidence rates of stroke recurrence, and the hazard ratios were also somewhat higher. 
The highest incidence rates were observed for the outcome of death. Overall, our 
findings are in agreement with those of a previous study from the Athens Stroke 
Registry.51 In this study, Ntaios et al. investigated the association of the CHADS2 and 
the CHA2DS2VASc score with the risk of recurrent ischemic stroke, death, and 
cardiovascular events in a minor non-AF stroke cohort.51 They stratified patients into 
low, intermediate and high-risk groups (“prestroke” CHADS2 and CHA2DS2VASc 
scores of 0, 1, and ≥2 respectively). They found that in the Cox proportional hazard 
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analyses, the risk of the outcomes increased with increasing risk scores, and the 
highest hazard ratio was observed for death. 
In our study, the C-statistics of the CHA2DS2VASc score for recurrent ischemic 
stroke and cardiovascular events were comparable and low, whereas the score 
performed reasonably well for prediction of death with C-statistics around 0.68. In 
another study from the Athens Stroke Registry, Ntaios et al. reported C-statistics of 
both the CHADS2 and the CHA2DS2VASc scores of 0.56 for the prediction of 
ischemic stroke recurrence in non-AF patients after a median follow-up of 30 
months.83 
Importantly, female sex is included in the CHA2DS2VASc score, but not in the Essen 
Stroke Risk Score. In the derivation cohort of the CHA2DS2VASc score1, female sex 
was associated with an odds ratio (OR) of thromboembolic events of 2.53 (95% CI 
1.08-5.92). In our study, we performed Cox proportional hazard analysis on the 
individual factors of the scores. The 1-year hazard ratio of female sex in recurrent 
ischemic stroke was 0.87 (95% CI 0.78-0.98). Hence, in our cohort, female sex 
actually seemed to be protective regarding the risk of ischemic stroke recurrence. The 
issue of female sex as a risk factor was also raised in a recent Danish study on 
thromboembolism in patients with incident AF.84 In this register-based study, female 
sex was associated with a hazard ratio of 0.77 (95% CI 0.55-1.13). Apart from female 
sex, all other factors included in the CHA2DS2VASc score and the Essen Stroke Risk 
Score were positively associated with ischemic stroke recurrence. 
The CHA2DS2VASc score was strongly associated with death. This is not surprising 
considering the factors comprised in the score: age is a very strong risk factor for 
death. Furthermore, congestive heart failure and vascular disease are also associated 
with high mortality.85,86 In the prediction of death, the C-statistic was higher for the 
CHA2DS2VASc score than for the Essen Stroke Risk Score. One possible explanation 
for this is found in the risk factor “smoking”, which is included in the Essen Stroke 
Risk Score. In the Cox proportional hazard analyses, smoking was associated with a 
hazard ratio of death of 0.59 (95% CI 0.56-0.63). The apparently lower mortality 
among smokers is also known from patients with coronary heart disease, where it is 
described as the “smoker’s paradox”.87 Our estimate was not adjusted for age, sex 
and comorbidities; however, in several studies of patients with acute myocardial 
infarction, this could not fully explain the paradox.87 It has been proposed that 
smokers may suffer more severe myocardial infarctions (and possibly, more severe 
ischemic strokes) and thereby have a higher pre-hospital mortality than non-smokers; 
however, this issue remains unsolved.88,89  
Conclusions on Study 1 
The CHA2DS2VASc score showed low discriminatory performance in the prediction 
of recurrent ischemic stroke and cardiovascular events. In terms of absolute risks, the 
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differences over the strata were of limited clinical significance. The Essen Stroke 
Risk Score performed marginally better than the CHA2DS2VASc score. Non-AF 
ischemic stroke patients have a high baseline risk of stroke recurrence, and the 
clinical variables included in the CHA2DS2VASc score and the Essen Stroke Risk 
Score showed only limited ability to differentiate between low-risk and high-risk 
patients. The results warrant caution before applying the scores in clinical practice, 
in particular for the endpoints of recurrent ischemic stroke and cardiovascular events.
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CHAPTER 4. WHITE MATTER 
HYPERINTENSITIES AND RECURRENT 
ISCHEMIC STROKE  
As shown in Study 1 and discussed in the previous chapter, the discriminatory 
performance of the CHA2DS2VASc score and the Essen Stroke Risk Score in the 
prediction of recurrent ischemic stroke was modest, and the absolute risks and hazard 
ratios varied only within a narrow interval. Improvement of the predictive accuracy 
of these risk scores will enhance their clinical utility, and the use of imaging markers 
of cerebral small vessel disease may be appropriate for this purpose. In the following 
sections, I will review the existing literature on the prognosis of white matter 
hyperintensities, look into aspects of how prediction models may be improved, and, 
finally, present and discuss the results of Study 2. 
4.1. WHITE MATTER HYPERINTENSITIES AND PROGNOSIS 
Ischemic Stroke 
In the general population, cerebral white matter hyperintensities are a risk factor for 
future ischemic stroke. This finding has been replicated in several studies.45,90–94 In 
contrast, the prognostic significance of white matter hyperintensities in patients with 
symptomatic ischemic cerebrovascular disease is been more disputed. Table 2 gives 
an overview of studies on white matter hyperintensities and the risk of recurrent 
stroke. 
The majority of the studies find that white matter hyperintensities are associated with 
the risk of recurrent stroke. Interestingly, this seems to apply to the short-term and 
the medium-term prognosis, but the association is vaguer in the very long-term 
prognosis. Melkas et al.95 followed 320 patients for up to 12 years. They reported an 
increased risk of ischemic stroke recurrence in patients with severe white matter 
hyperintensities after 5 years of follow-up. However, this effect was lost after 12 
years of follow-up. Putaala et al.96 followed a cohort of young ischemic stroke 
patients for a mean of 8.7 years and reported no association between white matter 
hyperintensities and the risk of ischemic stroke recurrence. Importantly, the mean age 
of this cohort was only 40.0 years; and therefore this association may not be directly 
comparable to the associations reported in the other studies. However, in the LiLAC 
study cohort,68 white matter hyperintensities were associated with an increased risk 
of stroke recurrence after a mean follow-up of 10.1 years (HR 1.64 (95% CI 1.28-
2.11)) in patients with TIA and minor stroke. 
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Table 2. Studies on white matter hyperintensities and recurrent stroke. 
Study N; age; 
imaging 
modality 
Main findings 
Miyao 
(1992)97 
N=215; mean 
age 71.3 years; 
CT 
Patients with first-ever stroke of lacunar type. After 1, 2, and 3 
years of follow-up, patients with WMHa showed a significantly 
higher cumulative incidence of stroke recurrence and death than 
age- and sex-matched patients without WMH. 
van 
Swieten 
(1992)98 
N=3,017; mean 
age 71.4/64.4 
years; CT 
Patients with transient ischemic attack or minor ischemic stroke. 
WMH were associated an increased risk stroke recurrence, HR 1.6 
(95% CI 1.2-2.2). 
Clavier 
(1994)99 
N=178; mean 
age not stated; 
CT and MRI 
Patients with symptomatic lacunar infarct. After a mean follow-up 
of 35 months, bivariate and multivariate analyses did not find 
WMHa to be associated with stroke recurrence. 
Podgorska 
(2002)100 
N=370; mean 
age 72/67 
years; CT 
Patients with ischemic and hemorrhagic (11.6%) stroke. WMHa 
were not significantly associated with increased risk of stroke 
recurrence after 1 year of follow-up. 
Streifler 
(2002)101 
N=2618; mean 
age not stated; 
CT 
Patients with symptomatic carotid stenosis (retinal or cerebral 
ischemia). After 3 years of follow-up, widespread WMHa were 
associated with higher risk of any stroke, HR 1.6 (95% CI 1.1-2,5) 
and HR 2.5 (95% CI 1.6-4.0) for medically and surgically treated 
patients, respectively. 
Hénon 
(2003)102 
N=202; 
median age 75 
years; CT 
Patients with ischemic and hemorrhagic (12%) stroke. After 3 
years of follow-up, WMHa were associated with an increased risk 
of stroke recurrence, RR 1.70 (95% CI 1.23-2.36) in multivariate 
analysis. 
Appelros 
(2005)103 
N=81; mean 
age 66.4 years; 
MRI 
Patients with lacunar infarcts. After 5 years of follow-up, WMH 
were associated with the risk of stroke recurrence, OR 1.7 (95% 
CI: 1.2-2.7), but not significantly with mortality. 
Fu (2005)104 N=228; mean 
age 50.5-75.9 
years; MRI 
Patients with first-ever ischemic stroke. After a mean follow-up of 
23.0 months WMH were associated with an increased risk of 
stroke recurrence, HR 4.18 (95% CI 2.04-8.56) as well as 
mortality, HR 2.02 (95% CI 1.03-3.96). 
van Wijk 
(2005)68 
N= 2447; mean 
age 65 years; 
CT 
Patients with TIA or minor stroke. After a mean follow-up of 10.1 
years, WMH were associated with the risk of stroke recurrence, 
HR 1.64 (95% CI 1.28-2.11), as well as mortality, HR 1.33 (95% 
CI 1.15-1.54). 
Putaala 
(2011)96 
N=655; mean 
age 40.0 years; 
MRI 
Patients with first-ever ischemic stroke. After a mean follow-up of 
8.7 years, WMHa were not associated with an increased risk of 
stroke recurrence, HR 1.07 (95% CI 0.40-2.85). Moderate-to-
severe WMH were associated with death from any cause, HR 3.43 
(95% CI 1.58-7.42). 
Melkas 
(2012)95 
N=320; mean 
age 70.8 years; 
MRI 
Patients with first-ever ischemic stroke. Severe WMH are a risk 
factor for recurrent ischemic stroke after 5 years of follow-up, HR 
1.80 (95% CI 1.11-2.95). After 12 years of follow-up, this effect 
was no longer significant. 
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Kim 
(2013)105 
N=2,378; 
median age 70 
years; MRI 
Patients with ischemic stroke. At 90 days, extensive periventricular 
WMH were associated with ischemic stroke recurrence, HR 1.67 
(95% CI 1.11-2.51). 
Kumral 
(2015)106 
N=9,522; mean 
age 65 years; 
MRI 
Patients with ischemic and hemorrhagic (9.3%) stroke. At 5 years, 
WMH were associated with increased risk of stroke recurrence in 
patients with index stroke caused by large-artery disease (OR 1.39 
(95% CI 1.18-1.64)) and small-artery disease (OR 1.57 (95% CI 
1.27-1.94)), but not in cardioembolic and “other” index stroke 
subtypes. 
Ntaios 
(2015)83 
N=1,892; 
median age 
71.0 years; CT 
and MRI 
Patients with first-ever ischemic stroke. After a median follow-up 
of 30.0 months, WMHa were associated with an increased risk of 
stroke recurrence in patients without AF (HR 1.82 (95% CI 1.31-
2.51)), but not in patients with AF (HR 1.02 (95% CI 0.63-1.66)). 
a) The authors applied the term “leukoaraiosis”. Abbreviations: CT, computed tomography; 
WMH, white matter hyperintensities; RR, relative risk; CI, confidence interval; MRI, 
magnetic resonance imaging; HR, hazard ratio; OR, odds ratio; AF, atrial fibrillation. 
 
 
Two recent studies reported their findings on the prognosis of white matter 
hyperintensities separately on subgroups of patients with suspected cardioembolic 
index stroke106 and patients with AF.83 None of these studies found any association 
between white matter hyperintensities and the risk of ischemic stroke recurrence in 
these two subgroups, whereas they confirmed a higher risk of stroke recurrence in 
those subgroups of patients who had large-artery atherosclerosis and small-artery 
disease-related stroke106 and those without AF.83  
To sum up, the majority of the previous studies evaluating the association between 
white matter hyperintensities and ischemic stroke recurrence find an increased stroke 
risk in patients with severe white matter hyperintensities. However, a recent well-
conducted study from Finland96 in young stroke patients and an older study100 found 
no association. Furthermore, the prognostic significance of white matter 
hyperintensities may differ with the time perspective and in cardioembolic versus 
non-cardioembolic ischemic stroke.  
Mortality and Cardiovascular Events 
In the general population, a number of studies have shown that white matter 
hyperintensities are associated with increased mortality.45,92,94,107 In a meta-analysis 
of these studies, the hazard ratio of death was 2.3 (95% CI 1.9-2.8) for severe white 
matter hyperintensities.108 
In ischemic stroke patients as well, white matter hyperintensities seem to be 
associated with an increased mortality. In recent studies, the hazard ratios of death in 
patients with moderate-to-severe white matter hyperintensities varied from 1.6 (95% 
CI 1.2-2.2) to 2.02 (95% CI 1.03-3.96).103,104,109 In the study by Putaala et al.96 in 
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young stroke patients, the adjusted hazard ratio of death from any cause was 3.42 
(95% CI 1.58-7.42) in patients with moderate-to-severe white matter hyperintensities 
after a mean follow-up of 8.7 years. In the Danish Copenhagen Stroke Study, 
leukoaraiosis had no significant influence on mortality.110 Debette et al.108 included 
four studies on high-risk patients in a meta-analysis of white matter hyperintensities 
and mortality. These studies comprised patients with stroke, headache, dizziness, and 
imbalance. White matter hyperintensities were associated with an increased mortality 
with a hazard ratio of 1.6 (95% CI 1.01-2.7). 
The association between white matter hyperintensities and the risk of cardiovascular 
events in stroke patients has only been reported in a limited number of studies. van 
Swieten et al.98 investigated the risk of cardiac events in patients with white matter 
hyperintensities and found a hazard ratio of 1.4 (95% CI 0.9-2.1). Puttala et al.96 
found an insignificantly lower risk of cardiovascular events in patients with severe 
white matter hyperintensities with a hazard ratio of 0.82 (95% CI 0.38-1.76). In the 
LiLAC study cohort68,  the long-term (mean 10.1 years) risk of vascular events was 
increased in those with white matter hyperintensities on CT with a hazard ratio 1.42 
(95% CI 1.22-1.66). 
To conclude, white matter hyperintensities seem to be associated with an increased 
mortality in ischemic stroke patients. The association between white matter 
hyperintensities and cardiovascular events is uncertain. 
4.2. IMPROVEMENT OF RISK PREDICTION MODELS 
One of the aims of Study 2 was to investigate the potential of including white matter 
hyperintensities as a measure to improve the predictive ability of the CHA2DS2VASc 
score and the Essen Stroke Risk Score. A basic requirement for a new predictor is its 
independent association with the outcome of interest. Hence, this must be evaluated 
before incorporating the predictor into the model. D’Agostino stated that “the new 
variable must be statistically significant and its relative risk must be clinically 
meaningful”.111 He proposed that an at least two-fold increase in relative risk from 
the first to the last quartile is reasonable. Based on the existing literature as cited 
above, it seems fair to assume that this could be true for white matter hyperintensities 
and stroke recurrence. 
Other factors to consider are the distribution or the prevalence of the predictor, the 
observer variability in the assessment of the predictor, and the weighting of the 
predictor.47 A predictor present in only 1% of the population is of questionable value. 
We know from the literature that white matter hyperintensities are a common finding; 
hence, this is not of major concern. The observer variability is a relevant 
consideration in our case. White matter hyperintensities can be graded on various 
rating scales and the presence of inter-observer variability cannot be disputed.43 We 
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chose to grade the radiological changes on the Fazekas scale which is relatively 
simple and among the most commonly applied rating scales.112 However, the issue 
of inter-observer variability of the rating should be more thoroughly explored before 
clinical application. The CHA2DS2VASc score as well as the Essen Stroke Risk Score 
are point-based models. To keep the simplicity of the concept of point-based models, 
we decided to add one point to the scores for a given cutoff of the severity of the 
white matter hyperintensities. 
A described in Chapter 3, the C-statistic is the most commonly applied statistical 
measure of model performance. In the evaluation of the performance of a new model, 
the C-statistic of the new and the old models can be compared. An increment in the 
C-statistic is equivalent to an improvement of the discriminatory performance of the 
model. However, it should be noted that models in which the original score has a 
relatively high C-statistic are relatively harder to improve in terms of a significantly 
higher C-statistic.74 We calculated and compared the C-statistics as the primary 
measure of model performance.  
The net reclassification improvement (NRI) has been proposed as a supplementary 
measure in the evaluation of new predictors.113 The NRI measures the number of 
individuals among events and non-events changing category after the addition of a 
new predictor. Among the individuals with the event of interest, a net reclassification 
upwards in risk category indicates that the predictor is beneficial. The opposite is true 
for the individuals without the event, that is, a downward reclassification is also 
considered beneficial. The total NRI is calculated as the sum of movements for events 
and non-events.74 The interpretation and the meaning of this measure has been 
disputed.114 However, here I report the NRI as an additional analysis as the 
reclassification table may offer useful information. 
Improving Stroke Risk Prediction with Neuroimaging 
Two previous studies have evaluated whether existing stroke risk scores can be 
improved by adding imaging markers of cerebral small vessel disease. Poels et al. 
applied data from the Rotterdam Scan Study and added information on silent brain 
infarcts and white matter hyperintensities to the Framingham Stroke Risk Function.93 
Their study was based on MRI scans from a population-based cohort and assessed 
the risk of incident stroke (ischemic and hemorrhagic). They found an improved 
accuracy of the 10-year stroke prediction when adding silent brain infarcts and 
periventricular white matter hyperintensities to the original score. No improvement 
was found for the addition of subcortical white matter hyperintensities. 
In a study from the Athens Stroke Registry83, the authors evaluated the potential 
improvement in the discriminatory performance of stroke prediction of the CHADS2 
and the CHA2DS2VASc scores when adding one point for leukoaraiosis on CT or 
MRI. The cohort comprised patients with incident ischemic stroke. None of the risk 
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scores showed improved discrimination when augmented with information on 
leukoaraiosis. Hence, the concept of adding neuroimaging markers of cerebral small 
vessel disease to existing risk score schemes has proved feasible. Yet, until now it 
has been confirmed only in a population-based cohort and as an extension of the 
Framingham Stroke Risk Function. 
4.3. STUDY 2 
Results 
Study 2 was a register-based cohort study on patients with incident ischemic stroke 
and no AF. Patients were identified in the Danish Stroke Registry. The study cohort 
was restricted to patients admitted to Aalborg University Hospital or Hjørring 
Hospital in the period from 1 January 2005 to 31 December 2012. Furthermore, only 
patients who underwent an MRI brain scan within 4 weeks after the index stroke were 
included. 
Review and rating of the MRI scans were a central part of this study. White matter 
hyperintensities were rated according to the Fazekas scale.112 Deep white matter 
hyperintensities (DWMH) and periventricular hyperintensities (PVH) were rated 
separately, and the total Fazekas score was calculated as the sum of the DWMH and 
the PVH (collectively referred to as the neuroimaging scores). We calculated 
recalibrated clinical scores by adding one point for white matter hyperintensities 
scores above various thresholds to the CHA2DS2VASc score and the Essen Stroke 
Table 3. C-statistics for the clinical scores, the combination of the clinical scores 
and a DWMH score ≥ 2, and the neuroimaging scores. 
  
Recurrent 
ischemic stroke 
 Death  
Cardiovascular 
events 
CHA2DS2VASc score  0.59 (0.51-0.65)  0.70 (0.64-0.77)  0.59 (0.54-0.65) 
Essen Stroke Risk Score  0.60 (0.53-0.68)  0.69 (0.62-0.76)  0.60 (0.55-0.65) 
CHA2DS2VASc score + 
DWMH score ≥2 
 0.62 (0.54-0.70)  0.72 (0.66-0.78)  0.61 (0.56-0.67) 
Essen Stroke Risk Score 
+ DWMH score ≥2 
 0.63 (0.56-0.71)  0.71 (0.65-0.77)  0.62 (0.57-0.67) 
DWMH score  0.65 (0.58-0.73)  0.65 (0.66-0.78)  0.59 (0.54-0.65) 
PVH score  0.62 (0.52-0.68)  0.66 (0.61-0.72)  0.58 (0.53-0.63) 
Total Fazekas score   0.65 (0.58-0.73)   0.67 (0.61-0.73)   0.60 (0.54-0.65) 
The CHA2DS2VASc score and the Essen Stroke Risk Score were recalibrated by adding 
one point for a DWMH score ≥2. Abbreviations: DWMH = deep white matter 
hyperintensity; PVH = periventricular hyperintensity. Data are C-statistics (95% CI). 
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Risk Score. C-statistics were calculated for the clinical scores, the recalibrated 
clinical scores, and the neuroimaging scores. 
The study comprised 832 patients with a mean age of 59.5 (standard deviation (SD) 
13.9) years. In the adjusted analyses, we found white matter hyperintensities to be 
significantly associated with the risk of recurrent ischemic stroke. There was a trend 
towards a significant association between white matter hyperintensities and the risk 
of death and cardiovascular events. The C-statistics are shown in Table 3. For the 
outcome of recurrent ischemic stroke, we found a statistically significant 
improvement of the C-statistics of the clinical scores when recalibrated by adding 
one point for a DWMH score ≥2 and a total Fazekas score ≥4. The differences were 
not significant for the thresholds of DWMH =3 and a total Fazekas score =6. For the 
outcomes of death and cardiovascular events, the C-statistics of the recalibrated 
scores were not significantly higher than the original scores. The numerically highest 
C-statistics were observed for the DWMH score and the total Fazekas score. 
However, these values were not significantly higher than those of the original scores. 
Table 4. Net reclassification improvement after 1 year of follow-up. 
      
Patients reclassified, 
n (%)   
    
   
With 
event 
Without 
event 
 NRI (95% CI) p-value  
Recurrent ischemic 
stroke 
       
 
CHA2DS2VASc + 
DWMH ≥2 
 17 (63.0) 281 (36.4)  0.52 (0.13-0.91) 0.009 
 
Essen Stroke Risk 
Score + DWMH ≥2 
 16 (59,3) 247 (32.0)  0.54 (0.16-0.91) 0.005 
Death        
 
CHA2DS2VASc + 
DWMH ≥2 
 15 (45.5) 351 (44.2)  0.02 (-0.32-0.36) 0.89 
 
Essen Stroke Risk 
Score + DWMH ≥2 
 14 (42.4) 212 (26.7)  0.31 (-0.03-0.65) 0.07 
Cardiovascular 
events 
       
 
CHA2DS2VASc + 
DWMH score ≥2 
 23 (40.3) 191 (25.8)  0.29 (0.02-0.56) 0.04 
  
Essen Stroke Risk 
Score + DWMH ≥2 
  23 (40.3) 191 (25.8)   0.29 (0.02-0.57) 0.04 
Abbreviations:  NRI = Net reclassification improvement; DWMH = deep white matter 
hyperintensity score.  
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Net reclassification improvement after 1 year of follow-up is shown in Table 4. The 
recalibrated models showed improved classification for the outcomes of recurrent 
ischemic stroke and cardiovascular events when adding 1 point for a DWMH score 
≥2. 
Study-Specific Methodological Considerations on Study 2 
As in Study 1, the study cohort in Study 2 was identified in the Danish Stroke 
Registry. We restricted the population to patients admitted to Aalborg University 
Hospital and Hjørring Hospital as these were the quantitatively largest stroke units in 
the North Denmark Region. We had access to imaging data only from examinations 
performed in this region. 
An important issue in the preparation of Study 2 was the management of the imaging 
data. CT was available in the majority of the patients, whereas MRI was available 
only in a subgroup of patients. The sensitivity and reproducibility of MRI rating of 
white matter hyperintensities are greater than those of CT,115,116 and most modern 
studies on this topic are based on MRI. Before the initiation of the studies, we 
assessed the number of MRI scans in the archives by counting the number of scans 
as there were no pre-existing imaging data in the patients. We found the number to 
be reasonable. We therefore chose to restrict the study population to patients with an 
available MRI brain scan. However, there were important demographic and clinical 
differences between the patients with and without an available MRI scan, which 
limits the generalizability of this study. 
Attention was paid to the fact that white matter hyperintensities may be of non-small 
vessel disease origin. Differential diagnoses of white matter hyperintensities include 
acquired as well as hereditary diseases like multiple sclerosis and 
leukodystrophies.117 Various patterns of distribution and localization of the white 
matter changes will raise suspicion of alternative underlying etiologies. The presence 
of other signs of small vessel disease (lacunes, microbleeds, enlarged perivascular 
spaces) supports the small vessel etiology.118 Cases of uncertainty were conferred 
with a consultant neuroradiologist and resolved by consensus discussion. 
In Study 1, more than one fourth of the patients died during follow-up and we 
therefore considered death a competing risk. In Study 2 and Study 3, about 9% of the 
study population died during follow-up. In these studies, we therefore chose to ignore 
the issue of competing risks. 
Discussion 
The findings obtained in Study 2 were in accordance with the findings from the 
majority of the studies listed in Table 2: White matter hyperintensities were 
associated with an increased risk of recurrent ischemic stroke, even after adjusting 
for vascular risk factors comprised in the CHA2DS2VASc score. Furthermore, this 
CHAPTER 4. WHITE MATTER HYPERINTENSITIES AND RECURRENT ISCHEMIC STROKE 
35 
study clearly demonstrated a dose-response relation between the burden of white 
matter hyperintensities and the risk of ischemic stroke recurrence. This was true for 
the deep as well as the periventricular white matter hyperintensities and for the total 
Fazekas score. Only one study listed in Table 2 assessed potential differences in the 
significance of deep versus periventricular hyperintensities. Kim et al.105 found that 
extensive periventricular but not subcortical white matter hyperintensities were 
associated with the 90-day stroke recurrence risk. This is surprising as it has been 
suggested that periventricular hyperintensities are of non-vascular origin.119 Our 
study did not support the indications of a substantially different prognostic value of 
periventricular versus deep white matter hyperintensities. 
We chose to add one point to the clinical scores for a DWMH score ≥2. In our data, 
the DWMH score was more strongly associated with the ischemic stroke recurrence 
risk than the PVH score. It is easier to assess the DWMH score than the total Fazekas 
score, especially for the non-radiologist, as only the deep white matter is rated. This 
is important for the clinical utility of the DWMH score which is intended for stroke 
neurologists. However, as shown in the sensitivity analyses, the results applied for a 
total Fazekas score ≥4 as well.  
The results of Study 2 are conceptually in accordance with those reported in the study 
by Poels et al.93 extending the Framingham Stroke Risk Function. On the other hand, 
the results contrast with the findings from the Athens Stroke Registry.83 In the 
interpretation of these apparently conflicting results, there are some essential 
methodological differences to consider. We, and Poels et al., applied exclusively MRI 
in the rating of the white matter hyperintensities. As a result, we were able to make a 
detailed rating and to differentiate between deep and periventricular changes. In the 
study based on the Athens Stroke Registry, both CT and MRI were allowed, and 
leukoaraiosis was reported only as present or not present. Though the applied rating 
scale is validated for the application in both CT and MRI,116 this may have hampered 
the study. Also, as we have shown, adding a point for moderate white matter 
hyperintensities (DWMH ≥2 or total Fazekas score ≥4) but not for the most severe 
changes (DWMH =3 or total Fazekas score =6) improved the discriminatory power. 
The rating of leukoaraiosis in the Greek study was not described in details; thus, it 
cannot be ruled out that “leukoaraiosis” in their terms represented only the most 
severe changes. 
Interestingly, the scores based solely on neuroimaging showed the best 
discriminatory performance in stroke recurrence prediction. The DWMH score and 
the total Fazekas score had C-statistics of 0.65, which were even better than the 
recalibrated clinical scores. The C-statistics of the neuroimaging scores were not 
statistically significantly higher than those of the clinical scores, although the 
recalibrated scores were significantly better. This paradox was caused by the close 
correlation between the clinical and the recalibrated clinical scores resulting in more 
narrow confidence intervals on the difference between these two scores. 
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Notwithstanding these statistical details, the neuroimaging scores proved useful in 
stroke recurrence prediction in our cohort. 
Several unanswered questions regarding white matter hyperintensities and ischemic 
stroke remain. Future studies should address the potentially different prognostic 
values of white matter hyperintensities in AF versus non-AF patients, the short-term 
prognosis versus the (very) long-term prognosis, and the deep versus the 
periventricular changes. We have proved the potential for improving clinical stroke 
risk scores by adding moderate-to-severe white matter hyperintensities as a predictive 
variable. However, the results should be confirmed in larger cohorts with more events 
and longer follow-up that will permit risk assessment in clinically relevant periods 
such as 1, 5, and 10 years. Moreover, future research should clarify whether risk 
scores based on white matter hyperintensities are superior to clinically based risk 
scores in stroke patients in general. An area of interest is whether there is a potential 
for enhancing the neuroimaging scores, for instance by combining various signs of 
small vessel disease or by adding selected clinical variables. 
Conclusions on Study 2 
In conclusion, white matter hyperintensities were associated with an increased risk 
of recurrent ischemic stroke in non-AF stroke patients. Second, the recalibration of 
the CHA2DS2VASc score and the Essen Stroke Risk Score with information on white 
matter hyperintensities resulted in improved discriminatory performance and 
improved classification. Third, the scores based solely on neuroimaging had the 
numerically highest C-statistics. 
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CHAPTER 5. SILENT LACUNES AND 
RECURRENT ISCHEMIC STROKE 
Lacunes are “black holes” in the brain – small fluid-filled cavities with imaging signal 
characteristics similar to those of the cerebrospinal fluid. Like white matter 
hyperintensities, lacunes are considered a sign of cerebral small vessel disease.33,38 A 
lacune may have been symptomatic or clinically silent. The clinical event 
corresponding to the symptomatic lacune is the lacunar stroke, resulting from a small 
brain infarct. Silent lacunes have no history of corresponding clinical symptoms. It 
remains unknown why some lacunes cause clinical symptoms, whereas others do 
not.120 Similarly, for unknown reasons, not all lacunar infarcts will cavitate and 
develop a lacune.121 
In Study 3, we aimed to investigate the association between silent lacunes and the 
risk of recurrent ischemic stroke, death, and cardiovascular events. Furthermore, we 
investigated the potential for enhancing clinical risk scores with silent lacunes. In this 
chapter, I will review the literature on the prognosis of silent lacunes and then present 
and discuss the results. 
5.1. SILENT LACUNES AND PROGNOSIS 
Ischemic Stroke 
Most of the current knowledge on the prognostic significance of silent lacunes comes 
from studies that investigated the prognosis of the broader concept of silent brain 
infarcts. No universally accepted definition of silent brain infarcts exists. However, 
usually all types of infarcts are included: lacunar infarcts, cortical infarcts as well as 
territorial infarcts. In the Rotterdam Scan Study, lacunes constituted 95% of the silent 
brain infarcts.40 Hence, it seems reasonable to assume that data from studies on silent 
brain infarcts largely apply in the prognosis of silent lacunes.   
The prevalence and prognostic role of silent brain infarcts have been investigated in 
large population-based cohorts. The prevalence of silent brain infarcts varies with 
age, from about 5-10% in those aged 60 years to 25-35% in those above 80 years.35 
In the Framingham Offspring Study45 and in the Rotterdam Scan Study,90 the 
presence of silent brain infarcts increased the risk of stroke about 3-fold. Of note, 
these studies did not differentiate between ischemic and hemorrhagic strokes. 
Table 5 summarizes studies on the prognosis of silent brain infarcts in ischemic stroke 
patients. The number of studies is limited compared with the literature on white 
matter hyperintensities. Two studies on the risk of stroke recurrence96,122 found an 
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increased risk of stroke recurrence after mean follow-up of 2 years and 8 years, 
respectively. In the study by Putaala et al.,96 this applied only for the presence on 
multiple (≥2) silent infarcts. In the study by de Jong et al.,122 the risk of stroke 
Table 5. Studies on silent brain infarcts and the risk of recurrent stroke and 
mortality. 
Study N; age; imaging 
modality 
Main findings 
Boon 
(1994)125 
N=755; mean 
age 71 (range 
24-96) years; CT 
Patients with first-ever supratentorial stroke. After 30 days, 
and 1 year of follow-up, ORs for death were 0.97 (0.51-
1.87) and 1.11 (0.73-1.70), respectively. No specific data on 
recurrent stroke. 
Jørgensen 
(1994)126 
N=500; mean 
age 74.3 (SD 
11.5) years; CT 
Patients with first-ever stroke (7.8% were hemorrhagic). 
Mortality rate during hospital stay did not differ. No specific 
data on stroke recurrence. 
Brainin 
(1995)127 
N=728; mean 
age 68 (SD 10) 
years; CT 
Patients with first-ever ischemic stroke. After 3 years of 
follow-up, there were no differences in mortality. No 
specific data on stroke recurrence. 
EAFT Study 
Group 
(1996)123 
N=985; mean 
age not stated; 
CT 
Patients with TIA or minor ischemic stroke and AF. 
Comparisons of patients with silent versus symptomatic 
lesions (a total of 532 patients) showed HR for recurrent 
stroke 1.18 (95% CI 0.79-1.77), HR for vascular events 1.2 
(95% CI 0.9-1.6). 
de Jong 
(2002)122 
N=333; mean 
age not stated; 
CT 
Patients with lacunar stroke. After a mean follow-up of 785 
(SD 479) days the OR for recurrent stroke was 2.09 (95% CI 
1.08-4.06) and the OR for mortality was 1.74 (95% CI 1.01-
3.01). The results were not significant at 30 days and 1 year 
of follow-up. 
Putaala 
(2011)96 
N=655; mean 
age 40.0 years; 
MRI 
Patients with first-ever ischemic stroke. After a mean 
follow-up of 8.3 (SD 4.0) years, HRs for recurrent stroke 
were 1.47 (0.68-3.16) for a single SBI and 2.48 (1.24-4.94) 
for multiple SBIs. Estimates for cardiovascular events and 
death were around 1.3, but not significant. 
Goia 
(2012)151 
N=170; mean 
age 39.4 (SD 
8.5) years; MRI 
Patients with first-ever ischemic stroke. After a mean 
follow-up of 26 (SD 23.0) months, silent ischemic lesions 
(leukoaraiosis or SBI) were associated with an HR of 3.2 
(95% CI 1.2-8.7) for recurrent stroke; the HR for recurrent 
stroke with the combination of SBI and leukoaraiosis was 
7.3 (2.3-22.9). No data on isolated SBI. 
Weber 
(2012)124 
N=207/207; 
mean age 66.1 
(SD 8.5) years; 
MRI 
Case-control study of patients with recent non-
cardioembolic stroke. After a mean follow-up of 2.5 years, 
OR for recurrent stroke was 1.42 (95% CI 0.79-2.46), OR 
for cardiovascular events was 1.38 (95% CI 0.81-2.33), and 
OR for death was 2.33 (95% CI 0.90-6.07). 
Abbreviations: CT, computed tomography; OR, odds ratio; SD, standard deviation; CI, 
confidence interval; HR, hazard ratio; MRI, magnetic resonance imaging; AF, atrial 
fibrillation; SBI, silent brain infarct. 
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recurrence was increased after 2 years of follow-up, whereas the risk was not 
significantly increased after 30 days or 1 year of follow-up. Two other studies on 
patients with AF123 and patients with non-cardioembolic stroke124 found no increased 
risk of stroke recurrence in the group with silent brain infarcts. 
Mortality and Cardiovascular Events 
Three older studies125–127 investigated the mortality in ischemic stroke patients during 
the hospital stay and during up to 3 years of follow-up. None of these studies found 
any differences between patients with or without silent brain infarcts. Nor did the two 
newer studies by Putaala et al.96 and Weber et al.124 find an increased mortality. Only 
in the study by de Jong et al.122 were silent infarcts associated with a statistically 
significantly increased risk of death at the end of follow-up. None of the studies found 
an increased risk of vascular events. 
To sum up, the existing literature indicates a possibly increased risk of stroke 
recurrence in ischemic stroke patients with silent brain infarcts. Most of the evidence 
indicates no increased risk of death in ischemic stroke patients with silent brain 
infarcts; nor does the risk of vascular events seem to be increased. 
5.2. STUDY 3 
Results 
The study cohort of Study 3 was identical to the study cohort of Study 2 with the 
exception that patients with a previous TIA were excluded. This produced a cohort 
of 786 patients with a mean age of 59.5 (SD 14.0) years. Analyses were stratified on 
the number of lacunes, classified as none, a single or multiple silent lacunes. As seen 
from Figure 1, the prevalence of silent lacunes was strongly dependent on age. 
Besides age, the presence of at least one silent lacune was more common in patients 
with congestive heart failure, hypertension, impaired renal function, in females, and 
in patients with moderate-to-severe white mater hyperintensities. The cumulative risk 
and the incidence rates of recurrent ischemic stroke and cardiovascular events 
increased with the number of silent lacunes. For the outcome of death, the correlation 
was more ambiguous. In the Cox proportional hazard analyses, the presence of 
multiple silent lacunes was associated with an increased risk of ischemic stroke 
recurrence. This finding persisted after adjustment for age, sex, and vascular risk 
factors. In the model additionally adjusted for white matter hyperintensities, the trend 
persisted, but it was statistically insignificant. We found no significant association 
between silent lacunes and the risk of death or cardiovascular events. 
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In additional analyses, the discriminatory performance of the CHA2DS2VASc score 
and the Essen Stroke Risk Score was investigated when recalibrated with one point 
for the presence of multiple silent lacunes. In the prediction of recurrent ischemic 
stroke, the improvements in terms of the C-statistic were minor and not statistically 
significant. The CHA2DS2VASc score versus the recalibrated CHA2DS2VASc score 
resulted in C-statistics of 0.58 (95% CI 0.51-0.67) and 0.60 (95% CI 0.52-0.69), 
respectively (p=0.098); the Essen Stroke Risk Score versus the recalibrated Essen 
Stroke Risk Score resulted in C-statistics of 0.61 (95% CI 0.53-0.69) and 0.62 (95% 
CI 0.55-0.70), respectively (p=0.187). 
Study-Specific Methodological Considerations on Study 3 
The considerations related to study cohort selection and generalizability described in 
the previous chapter on Study 2 apply in Study 3 as well. Besides these 
considerations, a number of other important potential weaknesses should also be 
considered. The correctness of “clinical silence” of the observed lacunes was based 
on the registry information. We excluded patients registered with a previous TIA. 
However, we still cannot guarantee that some patients with lacunes could have been 
assessed as symptomatic if the patient had been interviewed and examined clinically. 
Some TIAs or minor strokes may have caused subtle or odd symptoms that the 
patient, or even the doctor, did not react upon. If present, these events would represent 
potential cases of misclassification. 
Figure 1. Age-specific prevalence of ≥1 and ≥2 silent lacunes. 
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Another important consideration is the correct identification of lacunes. Of special 
concern is the confusion of lacunes and enlarged perivascular spaces, also known as 
Virchow-Robin spaces.38 Like lacunes, enlarged perivascular spaces show MRI 
signal characteristics similar to those of the cerebrospinal fluid and they are often 
located in the basal ganglia. These two entities are mainly distinguished by their size: 
perivascular spaces are smaller than 3 mm in diameter, whereas lacunes are larger 
than 3 mm. Lacunes are usually surrounded by a T2 hyperintense ring, which lacks 
in perivascular spaces.38,128 Moreover, enlarged perivascular spaces are usually 
multiple and symmetrically distributed. These features were carefully considered in 
the rating; however, some cases of misclassification cannot be precluded. It should 
also be noticed that the smallest lacunes could be missed due to the slice gap on the 
MRI, which is usually 5 mm. 
Discussion 
In terms of absolute risks, we demonstrated a moderate difference between patients 
with no versus multiple silent lacunes: After 3 years of follow-up, the risk of stroke 
recurrence was 5% versus 11%, respectively. In the multivariable model adjusted for 
age, sex, congestive heart failure, hypertension, diabetes, and vascular disease (model 
1 in Table 6), we found that multiple silent lacunes were associated with a 2.5 times 
higher risk of ischemic stroke recurrence.  
In comparison, a total Fazekas score of 6 was associated with a more than five times 
higher risk of stroke recurrence. Hence, white matter hyperintensities seem to be 
more closely associated with the risk of recurrent ischemic stroke than silent lacunes. 
Of note, the number of patients with multiple silent lacunes and the most severe 
Table 6. Cox proportional hazard analysis showing crude and adjusted 
hazard ratios of recurrent ischemic stroke. 
    Recurrent ischemic stroke 
Number of 
silent 
lacunes 
 
Crude HR 
(95% CI) 
Model 1 
Adjusted HR 
(95% CI)a 
Model 2 
Adjusted HR 
(95% CI)b 
0  Reference Reference Reference 
1  1.60 (0.71-3.62) 1.53 (0.67-3.49) 1.35 (0.58-3.11) 
≥2   3.05 (1.61-5.81) 2.52 (1.25-5.09) 1.62 (0.74-3.55) 
a) Model 1: Hazard ratios were adjusted for age, sex, congestive heart failure, 
hypertension, diabetes, and vascular disease. b) Model 2: Adjusted for the 
factors in model 1 and white matter hyperintensities. 
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grades of white matter hyperintensities (total Fazekas score 5-6) were almost the 
same in Study 3 – 11.1% versus 13.5%, respectively. As previously described, 
lacunes and white matter hyperintensities are both considered to be signs of cerebral 
small vessel disease, and the reasons for these considerable differences in the 
association with stroke recurrence are not obvious.  
One possible explanation is that lacunes form a more heterogeneous entity than white 
matter hyperintensities. We based the definition of lacunes on current 
recommendations,38 and the size is an important characteristic in this definition. The 
size limits may to some extent be arbitrary, and not all “true” lacunes may fall within 
these limits.33 Furthermore, it is not certain that silent lacunes constitute an 
independent entity.32 Others have argued that two types of lacunar infarction exist: 
one type related to small vessel disease and another type related to large-vessel 
atherosclerotic disease and embolism; and that these may differ in location.33,122 
Lacunes in the basal ganglia are presumably more likely to be caused by large-artery 
or cardiac embolism. Opposite, lacunes in the centrum semiovale most likely result 
from occlusion of small perforators.33 Hence, some silent lacunes may be of non-
small vessel disease origin which could blur the effect of “true” small vessel disease-
related silent lacunes. Of course, this implies that these two different entities carry 
different prognoses. Another observation of unknown significance is that some 
lacunes develop from lacunar infarcts, whereas others develop in areas of intense 
white matter hyperintensities without evidence of previous infarction.33 Hence, there 
are several unknown factors regarding the pathogenesis of lacunes. 
White matter hyperintensities were associated with an increased risk of death and 
cardiovascular events, whereas silent lacunes were not. This further indicates 
important differences in the prognostic significance of white matter hyperintensities 
and silent lacunes and supports that there may be different underlying 
pathogeneses,129 though these are so far largely unknown. 
In the additional model (model 2 in Table 6), we further adjusted for white matter 
hyperintensities. This considerably weakened the association between multiple silent 
lacunes and recurrent ischemic stroke, which was a consequence of the close 
association between silent lacunes and white matter hyperintensities as shown by a 
Goodman and Kruskal’s gamma of 0.695. The consequence of this is that for the 
purpose of risk prediction, silent lacunes will add no further value to a model already 
including white matter hyperintensities. Importantly, this does not necessarily imply 
that the presence of silent lacunes holds no prognostic information. As stated above, 
the presence of multiple silent lacunes more than doubles the risk of a second stroke 
during the first 3 years. However, in our analyses, silent lacunes showed no potential 
for significantly enhancing the discriminatory performance of the CHA2DS2VASc 
score or the Essen Stroke Risk Score. Poels et al. found very similar results in their 
population-based study.93 They added information on silent brain infarcts to the 
Framingham Stroke Risk Function and found only minor improvements in the C-
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statistic (0.01-0.04) with the greatest improvement in women. They did not report 
whether the improvements were statistically significant. 
Conclusions on Study 3 
Multiple silent lacunes were significantly associated with an increased risk of 
recurrent ischemic stroke in non-AF patients, but silent lacunes showed no potential 
for enhancing the discriminatory performance of the CHA2DS2VASc score or the 
Essen Stroke Risk Score in stroke risk prediction. There were no significant 
associations between silent lacunes and the outcomes of death and cardiovascular 
events. 
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CHAPTER 6. GENERAL 
METHODOLOGICAL 
CONSIDERATIONS 
All studies are subject to error. Different types of studies are prone to different types 
of error. Overall, errors can be either systematic or random. The former include bias 
and confounding, and precautionary measures can be taken to prevent these errors. 
Random errors are inevitable, but their significance can be reduced by increasing the 
size of the sample or study cohort.78 
Selection Bias 
Selection bias arises when the associations between the exposure and the outcome 
differs between those included in the study and those not included.78,130 In Study 1, 
we included all patients (except those with AF) registered in the Danish Stroke 
Registry with a diagnosis of incident ischemic stroke in the period 2003-2012. The 
completeness and the validity of this registry is high,9,82 and there are no indications 
that the included patients were not representative of Danish stroke patients. 
In Study 2 and Study 3, we also identified patients in the Danish Stroke Registry. 
Eligible patients were restricted to those admitted to Aalborg University Hospital and 
Hjørring Hospital in the period 2005-2012. This geographical restriction may have 
introduced a minor selection bias as differences between patients in different regions 
of the country may exist, such as disparities in lifestyle, comorbidities, and the 
willingness to seek medical care. However, a more severe selection bias was 
introduced by including only patients who underwent an MRI scan. As documented, 
these patients were younger, had less severe strokes, and a lower burden of 
comorbidities than those not included. Therefore, caution should be taken when 
generalizing the results to other populations. 
Information Bias 
Information bias refers to incorrect measuring or classification of information on the 
variables in the study. Incorrect classification, or misclassification, can be differential 
or non-differential.78,130 Either type of misclassification affects the estimates 
differently. In differential misclassification, the erroneous classification is related to 
other variables, and the effect on the estimates is unpredictable. Non-differential 
misclassification is misclassification unrelated to other variables and tends to draw 
the effect estimates towards neutrality.130 
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In Study 1, the exposures were the CHA2DS2VASc score and the Essen Stroke Risk 
Score. We applied previously validated algorithms for the calculation of the scores,49 
and we combined this information with data on comorbidities from the Danish Stroke 
Registry to increase sensitivity. Thus, in our algorithms, we were not able to identify 
patients with hypertension and diabetes treated with non-pharmacological methods. 
Individual assessment of the CHA2DS2VASc score and the Essen Stroke Risk Score 
by a physician may have resulted in different scores, and misclassification therefore 
cannot be ruled out. Any existing misclassification is, however, considered to be non-
differential. 
In Study 2 and Study 3, the exposures were the burden of white matter 
hyperintensities and the number of silent lacunes, respectively. The rating of the 
images was performed by the PhD student who had had training sessions with a 
consultant neuroradiologist. A reference panel of pre-rated images was regularly 
reviewed.131 The consultant neuroradiologist rated a validation sample, and we found 
acceptable agreement between the two raters. In no patients did we find 
disagreements of more than one point on the Fazekas scale. The rating of the images 
was performed blinded to all outcomes and variables; still, blinding of the civil 
registration number was not possible as knowledge of this this number was necessary 
to access the images. Thus, this could be a potential source of differentiated 
misclassification. 
The outcomes in all three studies were recurrent ischemic stroke, death, and 
cardiovascular events, though emphasis was on recurrent ischemic stroke. Diagnoses 
of recurrent stroke were identified in the Danish Stroke Registry, whereas all other 
diagnoses were identified in the Danish National Patient Registry. Recently, the 
Danish Stroke Registry was validated and the positive predictive value of a stroke 
diagnosis was found to be 90%.82 Information on death was obtained from the Danish 
Civil Registration System. No validation studies exist on this registry. However, in 
general the quality and coverage is assumed to be very high and no significant 
misclassification is suspected.132 Cardiovascular events were defined as the 
composite endpoint of ischemic stroke, TIA, myocardial infarction, and arterial 
thromboembolism. The positive predictive value of the TIA diagnosis in the Danish 
National Patient Registry is 58-68%.133,134 The negative predictive value is unknown. 
The positive predictive value of myocardial infarction is above 80%,135 whereas the 
validity of arterial thromboembolism is unknown. The validity of the TIA diagnosis 
is problematic. TIA constituted 29-40% of the events in the outcome of 
cardiovascular events, and the number of cardiovascular events may have been 
overestimated. This potential misclassification is suspected to be non-differential, 
hence drawing the estimates towards the null. 
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Confounding 
In epidemiology, confounding refers to the confusion of effects.78,136 A confounder 
must be associated with the exposure as well as the outcome. The confounder may 
not be an effect of the exposure, and it must be causally related to the outcome, or be 
a proxy for a cause of the outcome.78 Confounding is a systematic error and should 
be prevented by careful planning of the study and through the analyses; however, 
complete elimination of confounding is illusory. 
In all three studies, we restricted the study population to patients with incident 
ischemic stroke. This ensured a more homogenous study population and elimination 
of potential confounding from previous strokes. It is not the number of previous 
strokes per se that might confound the effects of the exposure, but this number could 
be a proxy for factors associated with the outcomes. 
In Study 1, we investigated the performance of two existing risk prediction models; 
and we did not aim to assess the direct effects of the exposure variables on the 
outcomes. Therefore, no further confounder control was included in the analyses. 
In Study 2 and Study 3, we investigated the effect of white matter hyperintensities 
and silent lacunes on the risk of the outcomes. We assumed that the risk factors 
included in the CHA2DS2VASc score were associated with the exposure (white 
matter hyperintensities and silent lacunes) and with the outcomes; furthermore, we 
did not consider the individual factors in the CHA2DS2VASc score to be 
intermediates between the exposure and the outcome. We accordingly adjusted for 
these potential confounders in the multivariable Cox proportional hazards models. In 
Study 3, we also included white matter hyperintensities in an additional model as 
previously discussed. 
Missing Data 
As described above, the CHA2DS2VASc score and the Essen Stroke Risk Score were 
calculated by combining information from The Danish Stroke Registry with data 
from the National Prescription Registry and the Danish National Patient Registry. In 
the two latter registries, there are no missing data as such – this is only a question of 
validity of the recorded diagnose. In The Danish Stroke Registry, the frequencies of 
missing data of the applied variables were as follows: diabetes 3.7%; previous 
myocardial infarction 4.6%; hypertension 4.9%; previous TIA 5.5%; peripheral 
arterial disease 8.6%; and smoking status 12.1%. Any data missing in the Danish 
Stroke Registry were coded as “not present”. No specific measures were taken to 
address missing data further. 
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Random Error 
In the previous paragraphs, I have discussed potential sources of systematic errors 
and how attempts were made to prevent them. Random errors are unexplained 
variability in the data.78,130 Generally, the significance of random errors will diminish 
with increasing size of the study population. This is reflected in the size of the 
confidence intervals of the estimate. Small samples much influenced by random 
errors have broad confidence intervals, whereas large samples with little influence 
from random errors have narrow confidence intervals.78 In the studies of this 
dissertation, efforts were made to maximize the size of the study cohorts and thereby 
to reduce random error. In Study 1, random error was a negligible problem. 
Outcome Misclassification 
The primary outcomes in all three studies were recurrent ischemic stroke, death, and 
cardiovascular events. It is possible that some cases of death were caused by 
undiagnosed stroke which would lead to misclassification. Regarding death, we 
assessed only all-cause mortality, though it would have been of interest to explore 
whether the clinical scores or the neuroimaging scores performed better in the 
prediction of stroke-related and/or cardiovascular death. To answer these questions, 
we would have needed access to reliable information on the causes of death. 
Information on the cause of death is available in the Danish Register of Causes of 
Death, which covers the entire Danish population since 1875 with diagnoses from the 
death certificates. However, it is open to doubt whether this could have answered the 
question satisfactorily as the validity of this register is debated.137 Therefore, we did 
not pursue this further. 
In all three studies, information on stroke subtype of the incident as well as the 
recurrent strokes would have strengthened the studies. A stroke subtype classification 
would have required review of the medical files and access to laboratory data and 
neuroimaging data from the recurrent strokes on all patients. The design of the studies 
and the anonymized processing of data did not allow for this.
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CHAPTER 7. CONCLUSIONS AND 
PERSPECTIVES 
The studies of this dissertation have contributed to clarify the value of contemporary 
clinical risk score schemes and neuroimaging signs of cerebral small vessel disease 
in the prediction of recurrent ischemic stroke, death, and cardiovascular events in 
non-AF patients with incident ischemic stroke. Validated risk stratification models 
are valuable clinical tools and may aid patient counseling and guide treatment 
decisions. 
We used the CHA2DS2VASc score as a starting point for the studies. This score 
system is used widely in the clinic for stroke and thromboembolic risk stratification 
in AF patients and, moreover, the score has been validated in a number of other 
patient categories. Despite the promising potential of the CHA2DS2VASc score in 
various groups of patients, it was of limited value in stroke recurrence prediction in 
our cohort of non-AF ischemic stroke patients. The baseline risk of stroke recurrence 
was relatively high for those patients with the lowest score, and the presence of 
additional risk factors increased the recurrence risk only moderately. This was also 
true for the Essen Stroke Risk Score. The included risk factors did, however, show 
an additive effect on the absolute and the relative risks, but the added risk for each 
factor was very moderate. This is underscored by comparison with for instance the 
Framingham stroke risk score.138 Therefore, the clinical utility of the CHA2DS2VASc 
score and the Essen Stroke Risk Score for the purpose of ischemic stroke recurrence 
prediction in non-AF patients is questionable, and based on the low discriminatory 
performance we cannot recommend routine clinical application of these scores for 
risk stratification purposes.  
We were not able to differentiate patients based on the underlying cause of the stroke. 
Our cohort comprised patients with various etiologies of ischemic stroke; large-artery 
disease, small vessel disease, rare causes, and unknown etiologies. We therefore 
cannot exclude that the scores could perform better in distinct subgroups of patients. 
This issue could be a potential topic for future studies; however, pursuit of this idea 
would detract from our original objective which was do develop a risk score that 
could easily be applied in all (non-AF) stroke patients without the need for advanced 
investigations. From a clinical perspective, it can be argued that for a large number 
of the ischemic stroke patients, the etiology is relatively easily determined; hence, a 
subdivision according to the underlying cause could be meaningful. 
The scores based on white matter hyperintensities showed the strongest association 
with the risk of stroke recurrence and the best discriminatory performance. The 
neuroimaging variables can be considered more specific in the sense that they are 
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directly related to the organ in question. Of course, this does not necessarily imply 
that they are better predictors of stroke recurrence risk; but the results presented in 
this dissertation confirm that in non-AF patients this is actually the case. The strong 
association between white matter hyperintensities and ischemic stroke recurrence 
resulted in a significantly better discriminatory performance of the clinical scores 
when recalibrated with one point for moderate-to-severe white matter 
hyperintensities. This important finding confirms the potential for enhancing existing 
scores with carefully selected new variables. Based on the results of Study 2, it may 
be speculated that recalibrating the Fazekas score or other neuroimaging scores with 
selected clinical variables could be a more advantageous approach resulting in even 
better discrimination. The size of our cohort did not allow for answering this question, 
but future studies with adequately sized cohorts are needed to explore this hypothesis. 
The prognostic value of silent lacunes was weaker than expected from the study on 
white matter hyperintensities. Though lacunes and white matter hyperintensities are 
both considered signs of cerebral small vessel disease, we conclude that in relation 
to ischemic stroke recurrence, the specificity of white matter hyperintensities is 
superior to that of silent lacunes. One reason for this may be that lacunes are a more 
heterogeneous entity than white matter hyperintensities. Recent studies have focused 
on the total burden of small vessel disease139,140 – that means including all the 
radiological signs connected to small vessel disease in a single rating: white matter 
hyperintensities, lacunes, enlarged perivascular spaces, and microbleeds. Perhaps 
such combined scales of all or a number of the variables will show even greater 
potential in stroke recurrence prediction than the focus on the individual signs 
presented here. Hopefully, future studies will show.   
At present, we cannot recommend any changes in clinical practice based on the 
results presented in this dissertation. However, in particular the presence of severe 
white matter hyperintensities in a patient with ischemic stroke should warrant careful 
evaluation of possible secondary preventive initiatives because these patients have an 
almost five times higher risk of stroke recurrence within the next three years 
compared to patients with no white matter changes.  
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APPENDIX A. THE ESSEN STROKE RISK SCORE 
The Essen Stroke Risk Score. 
Risk factors Points 
Age < 65 years 0 
Age 65-75 years 1 
Age > 75 years 2 
Hypertension 1 
Diabetes 1 
Previous MI 1 
Other cardiovascular disease 
(except MI and AF) 
1 
Peripheral arterial disease 1 
Smoking 1 
Additional TIA or ischemic stroke 
in addition to qualifying event 
1 
Abbreviations: MI, myocardial infarction; AF, atrial 
fibrillation; TIA, transient ischemic attack. 
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APPENDIX B. RISK SCORE SCHEMES IN STROKE 
Risk score schemes derived from TIA and stroke cohorts with multivariate models 
for stroke risk prediction. 
Study Population Endpoint Risk Factors 
Hankey141 
(1992) 
TIA Ischemic 
stroke 
within 1 or 
5 years 
Regression model including: Age; sex; 
amaurosis fugax versus brain TIA; vascular 
territory of TIA (carotid or vertebral); number 
of TIAs; PAD; left ventricular hypertrophy (on 
ECG); residual neurological signs 
The Dutch 
TIA Trial142 
(1993) 
TIA and 
ischemic stroke 
Stroke or 
major 
vascular 
events 
within 4 
years 
Regression model including: Age >65 years; 
sex; dysarthria; multiple attacks; symptoms >6 
weeks; hypertension; diabetes; prior MI; angina 
pectoris; intermittent claudication; hematocrit; 
CT characteristics (borders zone infarct, other 
infarcts, white matter lesions); ECG 
characteristics (anteroseptal infarct, ST 
depression, increased tem P wave, left 
ventricular hypertrophy) 
The 
California 
Score143 
(2000) 
TIA Ischemic 
stroke 
within 90 
days 
Point based model: Age >60 years; diabetes; 
duration of TIA (>10 minutes); weakness with 
TIA episode; speech impairment with TIA 
episode 
The Stroke 
Prognosis 
Instrument II 
(SPI-II)144 
(2000) 
TIA and 
ischemic stroke 
Stroke or 
death within 
2 years 
Point based model: Congestive heart failure (3 
points); diabetes (3 points); prior stroke (3 
points);  age >70 years (2 points); stroke as 
index event (not TIA) (2 points); hypertension 
(1 point); coronary artery disease (1 point) 
Essen Stroke 
Risk Score60 
(2005) 
TIA and 
ischemic stroke 
Ischemic 
stroke 
within 1-3 
years 
Point based model: 1 point for each factor: Age 
(65-75 years: 1 point; >75 years: 2 points), 
hypertension, diabetes, other CV disease 
(except MI and AF), PAD, smoking, previous 
TIA or ischemic stroke (in addition to 
qualifying event) 
LiLAC Study 
Group68 
(2005) 
TIA or ischemic 
stroke 
Ischemic 
stroke 
within 10 
years 
Regression model including: Sex; age; 
intermittent claudication; diabetes; 
hypertension; stroke versus TIA; paresis; 
dysarthria; white matter lesion (on CT); infarct 
(on CT); ST-depression (on ECG) 
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Pezzini145 
(2009) 
Incident 
ischemic stroke; 
age 15-49 years 
Ischemic 
stroke, TIA, 
or MI 
within 4 
years 
Point-based model: Hypertension; diabetes; 
smoking; hypercholesterolemia; migraine; 
family history of stroke; model enhanced with 
genetic factors. 
ABCD3-I 
Score73 
(2010) 
TIA Ischemic 
stroke 
within 2, 7, 
28, and 90 
days 
Point-based model: Age ≥60 years; BP ≥149/90 
mm Hg; clinical features: unilateral weakness, 
aphasia without weakness; duration: ≥60 
minutes or 10-59 minutes; diabetes; dual TIA 
(within 7 days); same-sided >49% internal 
carotid artery stenosis; MRI DWI 
hyperintensity 
Putaala69 
(2010) 
Incident 
ischemic stroke; 
age 15-49 years 
Ischemic 
stroke 
within 5 
years 
Regressions models (four) including: Age; sex; 
smoking; hypertension; heart failure; coronary 
heart disease; previous TIA; PAD; type 1 
diabetes; number of the above risk factors; 
stroke etiology 
RRE-9062 
(2010) 
Ischemic stroke Ischemic 
stroke 
within 90 
days 
Regression models (two) including: Etiologic 
stroke subtype; prior history of TIA or stroke; 
topography of index stroke; age; distribution of 
brain infarcts 
The Fukuoka 
Stroke Risk 
Score146 for 
Japanese 
(2012) 
Ischemic stroke Ischemic 
stroke 
within 1 
year 
Point-based model: Age (65-74 years, 1 point; 
≥ 75 years, 2 points); hypertension, diabetes, 
smoking, atrial fibrillation, chronic kidney 
disease, nonlacunar stroke, previous ischemic 
stroke. Separate data on non-cardioembolic 
stroke. 
Suzuki29 
(2012) 
Non-
cardioembolic 
ischemic stroke; 
age ≥45 years 
Ischemic 
stroke 
within 1 
year 
Regression model including: Age; sex; 
hypertension; hyperlipidemia; diabetes; waist 
circumference; previous stroke; modified 
Rankin scale 
Cámara147 
(2013) 
Incident 
ischemic stroke 
Ischemic 
stroke 
within 2 
years 
Algorithm including: Age <70 versus age >70; 
hypertensive cardiomyopathy / left ventricular 
hypertrophy; coronary heart disease; 
anticoagulant therapy; chronic kidney disease 
Sumi30 
(2013) 
Non-
cardioembolic 
ischemic stroke; 
age ≥45 years 
Ischemic 
stroke 
within 1 
year 
Regression model based on the Essen Stroke 
Risk Score with addition of waist 
circumference, stroke subtype, and sex 
Abbreviations: TIA, transient ischemic attack; PAD, peripheral arterial disease; ECG, 
electrocardiogram; MI, myocardial infarction; CT, computed tomography; CV, 
cardiovascular; AF, atrial fibrillation; MRI, magnetic resonance imaging; DWI, diffusion 
weighted imaging. The ABCD3-I score was developed from the ABCD148 Score and the 
ABCD2 149 Score (not shown). The Stroke Prognosis Instrument II (SPI-II) was developed 
from the SPI-I150 (not shown). 
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APPENDIX C. FIGURES OF CUMULATIVE RISK OF RECURRENT 
ISCHEMIC STROKE 
Cumulative risk of recurrent ischemic stroke stratified into six groups on the 
CHA2DS2VASc score (A) and the Essen Stroke Risk Score (B). The data source is 
the study population of Study 1. 
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Various clinical scoring systems have been developed for the risk stratification in cardiovascular and stroke medi-
cine. The CHADS
2
1 and, more recently, the CHA
2
DS
2
VASc2 
scores are based on well-recognized risk factors for stroke 
in atrial fibrillation (AF), including congestive heart failure, 
hypertension, age ≥75 years (2 points), diabetes mellitus, pre-
vious stroke or transient ischemic attack (2 points), vascular 
disease, age 65 to 74 years, and sex class (female). The scores 
have been validated in various cohorts3,4 and have become 
widely used for ischemic stroke risk stratification in patients 
with AF because of their simplicity.
To extend the possible application of these scores, there is 
some interest in validating the scores in non-AF patient pop-
ulations. The CHADS
2
 and the CHA
2
DS
2
VASc scores have 
been shown to be associated with the risk of stroke in non-AF 
patients with ischemic heart disease,5,6 in patients undergoing 
coronary artery bypass grafting,7,8 in patients with acute coro-
nary syndrome,9 and in addition, the scores hold promise for 
stroke and thromboembolism risk assessment in the general 
population.10
Risk stratification is of particular interest in patients with 
ischemic stroke as they are at high risk of a stroke recur-
rence (18% over a 5-year period11,12), and the recurrence risk 
is nonuniform across the population. A study based on the 
Athens Stroke Registry13 reported that the CHADS
2
 and the 
CHA
2
DS
2
VASc scores predict recurrent stroke and death in 
non-AF stroke patients. How these findings replicate in other 
patient populations is unknown. In addition, it is of interest 
to assess how the scores compare to risk scores developed 
specifically for the population of stroke patients. The Essen 
Background and Purpose—The CHA
2
DS
2
VASc score and the Essen Stroke Risk Score are respectively used for risk 
stratification in patients with atrial fibrillation and in patients with cerebrovascular incidents. We aimed to test the ability 
of the 2 scores to predict stroke recurrence, death, and cardiovascular events (stroke, transient ischemic attack, myocardial 
infarction, or arterial thromboembolism) in a nationwide Danish cohort study, among patients with incident ischemic 
stroke and no atrial fibrillation.
Methods—We conducted a registry-based study in patients with incident ischemic stroke and no atrial fibrillation. Patients 
were stratified according to the CHA
2
DS
2
VASc score and the Essen Stroke Risk Score and were followed up until stroke 
recurrence or death. We estimated stratified incidence rates and hazard ratios and calculated the cumulative risks.
Results—42 182 patients with incident ischemic stroke with median age 70.1 years were included. The overall 1-year incidence 
rates of recurrent stroke, death, and cardiovascular events were 3.6%, 10.5%, and 6.7%, respectively. The incidence rates, 
the hazard ratios, and the cumulative risk of all outcomes increased with increasing risk scores. C-statistics for both risk 
scores were around 0.55 for 1-year stroke recurrence and cardiovascular events and correspondingly for death around 
0.67 for both scores.
Conclusions—In this cohort of non–atrial fibrillation patients with incident ischemic stroke, increasing CHA
2
DS
2
VASc 
score and Essen Stroke Risk Score was associated with increasing risk of recurrent stroke, death, and cardiovascular 
events. Their discriminatory performance was modest and further refinements are required for clinical application.  
(Stroke. 2015;46:2491-2497. DOI: 10.1161/STROKEAHA.115.009912.)
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2
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Stroke Risk Score is one such risk score, which is conceptu-
ally similar to the CHA
2
DS
2
VASc score, in that it adds points 
according to presence of risk factors—1 point for each of 
age 65 to 75 years, age above 75 years (2 points however), 
hypertension, diabetes mellitus, myocardial infarction, other 
cardiovascular disease (except myocardial infarction and AF), 
peripheral arterial disease, smoking, and previous stroke or 
transient ischemic attack, resulting in maximum score of 9 
points.14,15
To evaluate how the CHA
2
DS
2
VASc score predicts recur-
rent stroke, death, and cardiovascular events, and in a first-
ever stroke population, and how this general score compares 
to the more specific Essen Stroke Risk Score, we conducted 
a large-scale observational cohort study using nationwide 
Danish registry data. We hypothesized that both risk scores 
would exhibit comparable associations with the risk of stroke 
recurrence, death, and cardiovascular events.
Methods
Registry Data Sources
The study was based on The Danish Stroke Registry, The Danish 
National Patient Registry, The National Prescription Registry, and 
The Danish Civil Registration System. All 4 registries cover the entire 
Danish population, and linkage was facilitated via the unique per-
sonal identification number assigned to all Danish residents.
The Danish Stroke Registry was established in 2003. It is manda-
tory for all Danish hospital departments treating stroke patients to 
report a standardized set of data to the registry, including diagno-
sis and various clinical variables, such as selected comorbidities and 
smoking habits.16 The Danish National Patient Registry17 has regis-
tered all hospital admissions with corresponding discharge diagnoses 
since 1977. Up to 1993, all diagnoses were coded according to the 
8th revision of the International Classification of Diseases (ICD-8), 
and since 1994, all diagnoses are coded according to the ICD-10. 
The National Prescription Registry18 holds data on all prescriptions 
dispensed from Danish pharmacies since 1994, coded according to 
the Anatomic Therapeutic Chemical Classification System. Finally, 
The Danish Civil Registration System contains information on date 
of birth, sex, migration, and vital status of all citizens.19
Study Population
The study population consisted of all patients aged 18 years or above, 
registered in The Danish Stroke Registry with an incident ischemic 
stroke (ICD-10 codes I63 or I64) in the period January 1, 2003, and 
December 31, 2012 (index stroke). The diagnosis of stroke in The 
Danish Stroke Registry is based on the judgment of the treating 
physician(s). This judgment is based on clinical and neuroimaging 
information gathered during the admission. The sensitivity of a stroke 
diagnosis has previously been shown to be 91% to 97%.20 To include 
only patients with incident stroke, we identified the first occurrence 
of registration of ischemic stroke for each patient in the registry. If 
this record stated that the patient had experienced a previous stroke 
(judged by the treating physician based on the available information: 
medical files, previous neuroimaging, patients, or proxy self-report), 
the patient was excluded. Patients with AF and patients who died <14 
days after the index stroke were excluded. To capture AF patients not 
diagnosed at a hospital, patients prescribed oral anticoagulants (war-
farin, phenprocoumon, dabigatran, rivaroxaban, and apixaban) within 
2 years before the index stroke were excluded.
To investigate potential differences between patients on second-
ary stroke prevention medications and the whole cohort, we identified 
a subgroup of patients treated with antiplatelet drugs (aspirin, clopi-
dogrel, and dipyridamole) and statins. Treatment with these drugs 
was defined as a claimed prescription of both drugs in the period from 
90 days before until 90 days after the index event.
Risk Scores
Based on information in the registries, the CHA
2
DS
2
VASc score and 
the Essen Stroke Risk Score were calculated for all patients at the 
time of admission for the incident stroke. We followed registry-based 
algorithms previously decribed3 and added information from The 
Danish Stroke Registry. Definitions of comorbidities applied in the 
risk scores can be found in the online-only Data Supplement.
Outcomes
Patients were followed from the date of the index stroke and until 
an event of interest or death. The events of interest were recurrent 
ischemic stroke or a cardiovascular event. Cardiovascular events were 
defined as the composite of ischemic stroke, transient ischemic at-
tack, myocardial infarction, or arterial thromboembolism. Follow-up 
was censored at time of emigration or end of study (December 31, 
2012). Information on emigration or death was available from the 
Danish Civil Registration System. Cardiovascular events were identi-
fied in The Danish Stroke Registry and The Danish National Patient 
Registry. Recurrence of ischemic stroke was ascertained from The 
Danish Stroke Registry, defining recurrent stroke as admission with 
a new stroke after discharge for the index event >14 days after the 
index stroke. This restriction was used to reduce the risk of capturing 
double registrations of the index stroke.
Statistical Analysis
Continuous data were summarized as mean values and standard de-
viations and categorical data as proportions. Event rates of recurrent 
ischemic stroke, death, and the composite cardiovascular end point 
were calculated for all patients, stratified by the CHA
2
DS
2
VASc score 
and the Essen Stroke Risk Score, respectively. Hazard ratios based 
on the Cox proportional hazards model were calculated for increas-
ing values of the CHA
2
DS
2
VASc score and the Essen Stroke Risk 
Score, setting as a reference a CHA
2
DS
2
VASc score of 2 and an Essen 
Stroke Risk Score of 0, respectively. Patients with CHA
2
DS
2
VASc 
score ≥7 were merged into one stratum, and similarly patients with 
Essen Stroke Risk Score ≥5 were merged into one stratum. Further, 
we calculated estimates of Cox proportional hazards for each of the 
(binary) components comprised in the 2 risk scores.
The cumulative risk of stroke and cardiovascular events were 
calculated using the Aalen–Johansen estimator, taking into account 
the competing risk of death. The cumulative risk of death was calcu-
lated using the standard Kaplan–Meier estimator. The discriminatory 
performance of the scores was assessed with C-statistics, taking into 
account competing risks of death.21 Negative predictive values (the 
proportion of patients with a score below the cut-off who remained 
event-free and alive during follow up) were calculated for the end 
points of stroke and cardiovascular events, with cutoff values of 2 
(CHA
2
DS
2
VASc) and 0 (Essen Stroke Risk Score), respectively.
We performed similar analyses for the subgroup of patients treat-
ed with antiplatelet drugs and statins.
Analyses were performed using Stata version 13 (Stata 
Corporation, College Station, TX). The study was performed and 
reported in accordance with the Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) recommendations.
Ethics
The study was approved by the Danish Data Protection Agency (File 
No. 2012-41-0633). In Denmark, no ethical approval is required for 
anonymous registry studies.
Results
In The Danish Stroke Registry, we identified 56 682 patients 
≥18 years with incident ischemic stroke in the period January 
1, 2003, to December 31, 2012. We excluded 3791 patients 
who died within 14 days after the index event, 9981 patients 
with AF, and 728 patients prescribed oral anticoagulants 
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within 2 years before the date of the index stroke. Hence, the 
study cohort consisted of 42 182 patients with first-ever isch-
emic stroke and no AF.
Baseline characteristics of the cohort are shown in Table 1. 
Patients were followed up for an average of 3.5 (standard 
deviation [SD] 2.7) years. Based on the CHA
2
DS
2
VASc score, 
all patients were assigned 2 points for the index stroke, result-
ing in a mean score of 4.3 (SD 1.4). The mean Essen Stroke 
Risk Score was 2.4 (SD 1.4).
The overall incidence rates of recurrent stroke, death, and 
cardiovascular events during the first year of follow up were 
3.6%, 10.5%, and 6.7% respectively. The corresponding over-
all incidence rates during the first 5 years of follow-up were 
2.4%, 7.1%, and 4.3% per year, respectively. The stratified 
incidence rates are shown in Table 2. In the Cox proportional 
hazard analyses, the hazard ratios increased with increasing 
risk scores as shown in Table 3. Correspondingly, the cumula-
tive risk of the outcomes increased with increasing risk score 
as shown in Figures 1 and 2.
Cox proportional hazard analyses for the single compo-
nents of the scores are found in Table I in the online-only Data 
Supplement. All components, except for female sex, were 
positively associated with the outcome of stroke recurrence. 
The strongest predictor of stroke recurrence was peripheral 
arterial disease. All factors were positively associated with the 
risk of death, except for smoking.
The Essen Stroke Risk Score had a marginally better dis-
criminatory performance in relation to stroke recurrence and 
cardiovascular event prediction than the CHA
2
DS
2
VASc score 
(Table 4), whereas the opposite was true regarding the pre-
diction of death. Similarly, the negative predictive values for 
stroke recurrence and cardiovascular events with a score of 2 
as cutoff value were marginally higher for the Essen Stroke 
Risk Score as shown in Table II in the online-only Data 
Supplement.
The subgroup treated with antiplatelet drugs and statins 
comprised 24 654 patients with a median age of 68.7 years 
(interquartile range 17.4 years), mean CHA
2
DS
2
VASc score 
4.3 (SD 1.4), and mean Essen Stroke Risk Score 2.5 (SD 
1.4). The overall incidence rates of recurrent stroke, death, 
and cardiovascular events during the first year of follow-up 
were 3.6%, 9.2%, and 5.5% respectively. The corresponding 
overall incidence rates during the first 5 years of follow-up 
were 2.3%, 7.1%, and 4.5% per year, respectively. The strati-
fied analyses are shown in Tables III and IV in the online-only 
Data Supplement. C-statistics for the subgroup (not shown) 
and the whole cohort were comparable.
Discussion
In this cohort study, we investigated the performance of 
the CHA
2
DS
2
VASc score and the Essen Stroke Risk Score 
for predicting stroke, death, and cardiovascular events in a 
nationwide cohort of non-AF patients with incident ischemic 
stroke. We found that increasing values of the CHA
2
DS
2
VASc 
score and the Essen Stroke Risk Score were associated with 
an increased risk of all 3 outcomes. The scores performed 
reasonably well in the prediction of survival free of stroke 
or cardiovascular events with negative predictive values for 
the lowest possible score around 0.95 and 0.85 (1-year and 
5-year follow-up, respectively) for both scores. When taking 
into account the competing risks of death, the discriminatory 
performance in stroke recurrence and cardiovascular events 
was modest, with C-statistics around 0.55 for both scores.
In accordance with previous studies in non-AF 
cohorts,5,6 we demonstrated increasing stroke risk with 
increasing CHA
2
DS
2
VASc score, and we found similar 
results for the Essen Stroke Risk Score. However, in this 
cohort of patients with incident ischemic stroke, important 
findings differentiate it from the non-stroke cohorts. First, 
the baseline incidence rates of stroke are considerably 
higher in our cohort. With the lowest possible scores, we 
find incidence rates of recurrent stroke of 2.0% per year for 
the Essen Stroke Risk Score (score of 0) and of 3.1% per 
year for the CHA
2
DS
2
VASc (score of 2). In The Heart & 
Table 1. Baseline Characteristics
Patients, n 42 182
Age, y
  Median 70.1
  Interquartile range 19.3
Age >65 y, % 63.4
Age >75 y, % 37.1
Female sex, % 45.7
Congestive heart failure, % 2.3
Hypertension, % 50.5
Diabetes mellitus, % 13.5
Vascular disease, % 14.2
Previous myocardial infarction, % 5.2
Peripheral arterial disease, % 7.4
Other heart disease, % 4.4
Smoking (current or previous), % 57.2
Previous TIA, % 4.7
CHA
2
DS
2
VASc score, mean (SD) 4.3 (1.4)
CHA
2
DS
2
VASc score, %
  2 11.9
  3 20.8
  4 23.4
  5 22.4
  6 15.7
  ≥7 5.8
Essen Stroke Risk Score, mean (SD) 2.4 (1.4)
Essen Stroke Risk Score, %
  0 6.3
  1 20.8
  2 26.3
  3 25.9
  4 14.1
  ≥5 6.8
CHA
2
DS
2
VASc indicates congestive heart failure, hypertension, age ≥75 y 
(2 points), diabetes mellitus, previous stroke or transient ischemic attack (TIA; 
2 points), vascular disease, age 65–74 y, and sex class (female); SD, standard 
deviation; and TIA, transient ischemic attack.
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Soul Cohort5 of patients with stable coronary heart disease, 
the annual incidence rate of stroke and transient ischemic 
attack was 0.9% for a CHADS
2
 score of 2. In their study 
on patients with acute coronary syndrome, Mitchell et al6 
reported an annual incidence rate of stroke below 1% for 
all values of the CHA
2
DS
2
VASc score (stratified as 1, 2, 3, 
and ≥4), except for previous stroke or transient ischemic 
attack, which resulted in an annual stroke incidence rate of 
1.54%, which is comparable to the baseline risk in our study. 
Second, the difference in stroke incidence rate between 
the lowest and the highest risk score is limited, which is 
reflected in the low hazard ratios, which only in the Essen 
Table 3. Cox Proportional Hazard Analysis Showing 1- and 5-year Hazard Ratios of Stroke, Death, and Cardiovascular Events 
Stratified by the CHA2DS2VASc Score and the Essen Stroke Risk Score
1-y Hazard Ratio 5-y Hazard Ratio
Stroke Death Cardiovascular Events Stroke Death Cardiovascular Events
CHA
2
DS
2
VASc Score
  2 Ref. Ref. Ref. Ref. Ref. Ref.
  3 0.87 (0.70–1.07) 1.41 (1.14–1.75) 1.02 (0.86–1.19) 1.06 (0.91–1.22) 1.37 (1.20–1.55) 1.16 (1.04–1.30)
  4 1.20 (0.98–1.46) 3.36 (2.77–4.07) 1.38 (1.19–1.61) 1.37 (1.19–1.57) 3.04 (2.71–3.42) 1.55 (1.39–1.72)
  5 1.25 (1.02–1.52) 5.32 (4.41–6.43) 1.32 (1.13–1.54) 1.56 (1.35–1.79) 5.01 (4.48–5.62) 1.62 (1.45–1.80)
  6 1.27 (1.03–1.57) 7.47 (6.18–9.03) 1.52 (1.29–2.39) 1.72 (1.48–1.99) 6.66 (5.94–7.47) 1.91 (1.71–2.14)
  ≥7 1.56 (1.20–2.02) 9.84 (8.06–12.02) 1.97 (1.63–2.39) 1.90 (1.58–2.29) 8.93 (7.89–10.10) 2.36 (2.05–2.71)
Essen Stroke Risk 
Score
  0 Ref. Ref. Ref. Ref. Ref. Ref.
  1 1.46 (1.07–1.98) 1.31 (1.00–1.70) 1.45 (1.15–1.82) 1.47 (1.19–1.82) 1.55 (1.30–1.85) 1.41 (1.21–1.65)
  2 1.57 (1.16–2.13) 3.35 (2.62–4.29) 1.60 (1.25–2.01) 1.80 (1.46–2.21) 3.86 (3.26–4.56) 1.75 (1.50–2.04)
  3 2.11 (1.57–2.83) 4.97 (3.90–6.34) 1.98 (1.58–2.47) 2.41 (1.97–2.96) 6.09 (5.15–7.18) 2.23 (1.91–2.59)
  4 2.16 (1.58–2.94) 5.85 (4.57–7.49) 2.28 (1.81–2.87) 2.65 (2.14–3.28) 7.26 (6.14–8.60) 2.69 (2.30–3.15)
  ≥5 2.30 (1.64–3.22) 7.06 (5.47–9.10) 2.87 (2.24–3.66) 2.81 (2.22–3.54) 8.98 (7.55–10.69) 3.44 (2.91–4.07)
Data are hazard ratios (95% confidence intervals). Ref. indicates reference. Cardiovascular events represent the composite end point of stroke, transient ischemic 
attack, myocardial infarction, or arterial thromboembolism. CHA
2
DS
2
VASc indicates congestive heart failure, hypertension, age ≥75 y (2 points), diabetes mellitus, 
previous stroke or transient ischemic attack (TIA; 2 points), vascular disease, age 65–74 y, and sex class (female); and TIA, transient ischemic attack.
Table 2. One- and 5-year Incidence Rates per 100 Person-Years of Stroke, Death, and Cardiovascular Events, Stratified by the 
CHA2DS2VASc Score and the Essen Stroke Risk Score
1-y Rates 5-y Rates
Stroke Death
Cardiovascular 
Events Stroke Death
Cardiovascular 
Events
CHA
2
DS
2
VASc 
Score
Events, n Rate Events, n Rate Events, n Rate Events, n Rate Events, n Rate Events, n Rate
  2 143 3.1 119 2.6 230 5.1 281 1.7 335 1.9 455 2.8
  3 215 2.7 292 3.6 405 5.2 506 1.8 779 2.7 900 3.3
  4 325 3.8 764 8.7 602 7.1 686 2.4 1825 6.0 1244 4.5
  5 315 4.0 1130 13.9 535 6.8 701 2.7 2688 10.0 1175 4.7
  6 219 4.1 1082 19.7 418 7.9 499 3.1 2289 13.5 891 5.7
  ≥7 95 5.0 507 26.2 192 10.3 185 3.5 1026 18.4 367 7.2
Essen Stroke 
Risk Score
  0 49 2.0 68 2.8 88 3.7 104 1.2 146 1.6 188 2.1
  1 234 3.0 293 3.6 417 5.3 491 1.7 733 2.5 850 3.1
  2 309 3.2 921 9.4 564 5.9 702 2.1 2130 6.2 1226 3.9
  3 396 4.3 1316 14.0 666 7.4 858 2.9 3071 9.9 1418 5.0
  4 216 4.4 826 16.6 407 8.5 480 3.3 1862 12.0 867 6.2
  ≥5 108 4.7 470 20.2 240 10.8 223 3.6 1000 15.2 483 8.2
Cardiovascular events represent the composite end point of stroke, transient ischemic attack, myocardial infarction, or arterial thromboembolism. CHA
2
DS
2
VASc 
indicates congestive heart failure, hypertension, age ≥75 y (2 points), diabetes mellitus, previous stroke or transient ischemic attack (2 points), vascular disease, 
age 65–74 y, and sex class (female).
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Stroke Risk Score exceed a value of 2. That means, adding 
further risk factors does increase the stroke risk, but only 
modest, as seen from a 1-year stroke recurrence hazard ratio 
of 1.56 (1.20–2.02) for a CHA
2
DS
2
VASc score ≥7. Hence, 
previous stroke or thromboembolism confers a much higher 
baseline risk, which outweighs the impact of the other risk 
factors. However, in AF-patients as well, it seems that previ-
ous thromboembolism plays a special role, as reported in a 
recent Danish study.22 In that study, it was shown that pre-
vious thromboembolism as defined in the CHA
2
DS
2
VASc 
score adds more than the double to the total risk of stroke 
and other thromboembolic events than does the sum of any 
other 2 risk factors in the CHA
2
DS
2
VASc score.
We found the 5-year cumulative risks of stroke recurrence 
in the CHA
2
DS
2
VASc baseline group to be comparable to the 
results of the study from the Athens Stroke Registry (around 
7% to 9%).13 By contrast, in the high risk groups, we found the 
cumulative risk of stroke recurrence to be somewhat lower: 
around 10% for a CHA
2
DS
2
VASc score ≥5 versus almost 20% 
for a CHA
2
DS
2
VASc score ≥2 in the Greek study (they did 
not count the incident stroke in the score). The Greek cohort 
was established over a wide time span (1993–2011), possibly 
resulting in greater inhomogeneity in treatment and recur-
rence risk, but also the influence of competing risks must be 
considered. From the total number of deaths, which in the 
present study exceeds 25%, it is clear that competing risks 
must be taken into account to avoid overestimating the risk 
of stroke.22,23
The Essen Stroke Risk Score is marginally superior to the 
CHA
2
DS
2
VASc score in stroke recurrence prediction when 
assessed with the C-statistics and estimates of the negative 
predictive values of the lowest possible score. In the Cox 
regression analysis of the single components of the scores, we 
find that female sex is significantly protective against recurrent 
stroke with a hazard ratio of 0.87 (95% confidence interval, 
0.78–0.98) in the first year. This explains, at least partly, the 
difference between the 2 scores because sex is not comprised 
Figure 1. Five-year cumulative risk of stroke recurrence (A), 
death (B), and cardiovascular events (C) stratified by the 
CHA2DS2VASc score. The cumulative risks of stroke recurrence 
and cardiovascular events were assessed with death as compet-
ing risk. CHA2DS2VASc indicates congestive heart failure, hyper-
tension, age 75 y (2 points), diabetes mellitus, previous stroke 
or transient ischemic attack (2 points), vascular disease, age 
65–74 y, and sex class (female).
Figure 2. Five-year cumulative risk of stroke recurrence (A), death 
(B), and cardiovascular events (C) stratified by the Essen Stroke 
Risk Score. The cumulative risks of stroke recurrence and cardio-
vascular events were assessed with death as competing risk.
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in the Essen Stroke Risk Score, and it emphasizes difficulties 
in applying the CHA
2
DS
2
VASc score in a non-AF cohort.
In the subgroup analyses of patients treated with antiplate-
let drugs and statins, the rates of death and cardiovascular 
events after the first year of follow-up were marginally lower 
in the treatment group, but these differences disappeared after 
5 years of follow up, not affecting the overall conclusion of 
the study.
Clearly, as shown in this study, stroke patients are at high 
risk of new cardiovascular events, and even at higher risk of 
death. The discriminatory performance of the scores in predic-
tion of cardiovascular events is comparable to previous evalu-
ations of The Essen Stroke Risk Score24 and is only modest. 
Overall, the performance in the prediction of death is some-
what better, which may be attributable to the strong influence 
of age on this outcome.
Strengths and Limitations
The main strength of this study is the nationwide design result-
ing in a large cohort with a large number of events in all strata. 
Our study is limited by its observational nature based on reg-
istry data. The diagnosis of stroke relies on correct diagnosis 
in The Danish Stroke Registry, which has previously been 
validated, showing a positive predictive value of 90% of a 
stroke diagnosis.20 We are not able to rule out that some cases 
of death could be caused by undiagnosed stroke as we do not 
have access to information of causes of death on all patients.
The frequency of risk factors in the cohort and the cal-
culation of the risk scores may differ from the results of an 
individual assessment by a physician. However, we used a 
combination of previously validated algorithms3 and informa-
tion from The Danish Stroke Registry to optimize the sensitiv-
ity of our comorbidity diagnoses.
Conclusions
The CHA
2
DS
2
VASc score and the Essen Stroke Risk Score 
predicted stroke, death, and cardiovascular events in this 
nationwide cohort of patients with incident ischemic stroke. 
Future refinements of clinical risk scores are required and 
decision-making based on these scores may not be warranted 
at present. Reliable risk stratification will enable the clinician 
to point out high risk patients who may benefit from a more 
intense follow-up and a more rigorous approach to the modifi-
able risk factors and have consequences for the choice(s) of 
antithrombotic treatment.
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1 
ONLINE SUPPLEMENT 
Recurrent Stroke – The Value of the CHA2DS2VASc Score and the Essen Stroke Risk 
Score in a Nationwide Stroke Cohort 
The online supplement contains: 
Definitions of comorbidities 
Table I. Cox Proportional Hazard Analysis of Ratios of Stroke, Death, and Cardiovascular 
Events based on the Components of the CHA2DS2VASc Score and the Essen Stroke Risk 
Score 
Table II. Negative Predictive Values for the CHA2DS2VASc Score and the Essen Stroke Risk 
Score 
Table III. Incidence Rates of Stroke and Death Stratified by the CHA2DS2VASc Score and 
the Essen Stroke Risk Score in the Subgroup of Patients Treated with Antiplatelet Drugs and 
Statins. 
Table IV. Cox Proportional Hazard Analysis of Stroke, Death, and Cardiovascular Events 
Stratified by the CHA2DS2VASc Score and the Essen Stroke Risk Score in the Subgroup of 
Patients Treated with Antiplatelet Drugs and Statins. 
2 
Definitions of comorbidities 
International Classification of Diseases (ICD)-8 and 10 codes and Anatomical Therapeutic 
Chemical (ATC) prescription codes applied for identification in the registries 
Atrial fibrillation (AF) was determined as a diagnosis in the Danish National Patient Registry 
(ICD-8 and ICD-10 codes 42793, 42794, I48) or a diagnosis of AF in The Danish Stroke 
Registry. 
Congestive heart failure was determined as the combination of a prior diagnosis of heart 
failure in The Danish National Patient Registry (ICD-8 and ICD-10 codes 42709, 42710, 
42711, 42719, 42899, 78249, I110, I130, I132, I420, I50) and the prescription of a loop 
diuretic (C03C).  
Hypertension was determined as a diagnosis of hypertension in The Danish National Patient 
Registry (ICD-8 and ICD-10 codes 400-404, 41009, 41109, 41209, 41309, 41409, 43000, 
43001, 43008, 43009, 43100, 43101, 43108, 43109, 43200, 43201, 43202, 43208, 43209, 
43309, 43409, 43509, 43600, 43601, 43609, 43700, 43701, 43708, 43709, 43809, I10-I15) 
therapy with at least two different classes of antihypertensive drugs, namely α adrenergic 
blockers (ATC-codes C02A, C02B, C02C), non-loop diuretics (ATC-codes C02DA, C02L, 
C03A, C03B, C03D, C03E, C03X, C07C, C07D, C08G, C09BA, C09DA, C09XA52), 
vasodilators (ATC-codes C02DB, C02DD, C02DG, C04, C05), β blockers (ATC-code C07), 
calcium channel blockers (ATC-codes C07F, C08, C09BB,C09DB), and renin-angiotensin 
system inhibitors (ATC-code C09) or a diagnosis of hypertension in The Danish Stroke 
Registry. 
Diabetes mellitus was determined as a diagnosis of diabetes mellitus (ICD-8 and ICD-10 
codes 24900, 24909, 25008, 25009, E100, E101, E109, E110, E111, E119) in The Danish 
National Patient Registry, the prescription of antidiabetics (ATC-code A10) or a diagnosis of 
diabetes mellitus in The Danish Stroke Registry. 
Previous thromboembolism: In the CHA2DS2VASc score all patients were assigned two 
points for the index stroke. 
Vascular disease (myocardial infarction, peripheral arterial disease and aortic plaque) was 
determined as a diagnosis in The Danish National Patient Registry (ICD-8 and ICD-10 codes 
410, I21, I23, 440, 441, 442, 443, 444, 445, I702, I703, I704, I705, I706, I707, I708, I709, 
I71, I739, I700) or a diagnosis of previous myocardial infarction and/or peripheral arterial 
disease in The Danish Stroke Registry. 
Previous myocardial infarction was determined as a diagnosis in The Danish National Patient 
Registry (ICD-8 and ICD-10 codes 410, I21, I23) or a diagnosis of previous myocardial 
infarction in The Danish Stroke Registry. 
3 
Other cardiovascular disease was determined as a diagnosis (ICD-10 codes I20, I22, I24, 
I25, I30-I39, I40-I47, I49, I50, I51, I52) or a procedure code (FNG/A/C/D/E) in The Danish 
National Patient Registry. 
Peripheral arterial disease was determined as a diagnosis in The Danish National Patient 
Registry (ICD-8 and ICD-10 codes 440, 441, 442, 443, 444, 445, I702, I703, I704, I705, 
I706, I707, I708, I709, I71, I739) or a diagnosis of peripheral arterial disease in the DRS. 
Smoking was determined as current or previous smoking according to The Danish Stroke 
Registry. 
Additional transient ischemic attack (TIA) or ischemic stroke was determined a diagnosis of 
TIA in The Danish National Patient Registry (ICD-8 and ICD-10 codes 43509, 43599, G45) 
or a diagnosis of previous TIA in The Danish Stroke Registry. Patients with previous 
ischemic stroke were not included in the cohort. 
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5 
Table II. Negative Predictive Values for the CHA2DS2VASc Score and the Essen Stroke Risk 
Score 
Endpoint CHA2DS2VASc Score 
Essen Stroke 
Risk Score 
Stroke 1-year 0.94 (0.94-0.95) 0.95 (0.94-0.96) 
5-year 0.84 (0.83-0.85) 0.88 (0.87-0.89) 
Cardiovascular 
Events 
1-year 0.93 (0.92-0.93) 0.94 (0.93-0.95) 
5-year   0.80 (0.79-0.81)   0.84 (0.82-0.86) 
The negative predictive values are estimates of the proportion of patients with a score at or 
below the cut-off who remained event-free and alive during follow up. Cutoff values were 2 
(CHA2DS2VASc) and 0 (Essen Stroke Risk Score). Cardiovascular events represent the 
composite endpoint of stroke, transient ischemic attack, myocardial infarction or arterial 
thromboembolism. CHA2DS2VASc indicates congestive heart failure, hypertension, age ≥ 75 
years (2 points), diabetes mellitus, previous stroke or transient ischemic attack (2 points), 
vascular disease, age 65-74 years and sex class (female). 
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Abstract 
Background: Nearly one in five patients with ischemic stroke will experience a 
second stroke within five years. Stroke risk stratification schemes based solely on 
clinically variables perform only modest in non-atrial fibrillation (AF) patients and 
improvement of these schemes will enhance their clinical utility. Cerebral white 
matter hyperintensities are associated with an increased risk of incident ischemic 
stroke in the general population whereas the association with the risk of ischemic 
stroke recurrence is more ambiguous. In a non-AF stroke cohort we investigated the 
association between cerebral white matter hyperintensities and the risk of recurrent 
ischemic stroke, and we evaluated the predictive performance of the CHA2DS2VASc 
score and The Essen Stroke Risk Score (clinical scores) when augmented with 
information on white matter hyperintensities. 
Methods: In a registry-based, observational cohort study, we included 832 patients 
(mean age 59.6 (SD 13.9) years; 42.0% females) with incident ischemic stroke and 
no AF. We assessed the severity of white matter hyperintensities on magnetic 
resonance imaging. Hazard ratios stratified by the white matter hyperintensities score 
and adjusted for the components of the CHA2DS2VASc score were calculated based 
on Cox proportional hazards analysis. Recalibrated clinical scores were calculated by 
adding one point to the score for the presence of white matter hyperintensities. The 
discriminatory performance of the clinical scores, the recalibrated scores, and the 
white matter hyperintensities score was assessed with the C-statistic. 
Results: White matter hyperintensities were significantly associated with the risk of 
recurrent ischemic stroke after adjusting for clinical risk factors: The hazard ratios 
ranged from 1.65 (95% CI: 0.70-3.86) for mild changes to 5.28 (1.98-14.07) for the 
most severe changes. C-statistics for the prediction of recurrent ischemic stroke were 
0.59 (0.51-0.65) for the CHA2DS2VASc score and 0.60 (0.53-0.68) for the Essen 
Stroke Risk Score. The recalibrated clinical scores showed improved C-statistics: the 
recalibrated CHA2DS2VASc score 0.62 (0.54-0.70) (p=0.024) and the recalibrated 
Essen Stroke Risk Score 0.63 (0.56-0.71) (p=0.031). C-statistics of the white matter 
hyperintensities score were 0.62 (0.52-0.68) to 0.65 (0.58-0.73). 
Conclusions: Increasing burden of white matter hyperintensities was independently 
associated with recurrent ischemic stroke in a cohort of non-AF ischemic stroke 
patients. Recalibration of the CHA2DS2VASc score and the Essen Stroke Risk Score 
with information on white matter hyperintensities led to improved discriminatory 
performance in ischemic stroke recurrence prediction. Risk scores based on white 
matter hyperintensities alone were at least as accurate as the established clinical risk 
scores in the prediction of ischemic stroke recurrence. 
Introduction 
In ischemic stroke patients, risk stratification score systems for the individual 
assessment of stroke recurrence risk are of great clinical relevance. The risk of stroke 
recurrence can be as high as 18% over a 5-year period [1,2], but varies considerably 
among patients. In patients with atrial fibrillation (AF) the CHA2DS2VASc 
(congestive heart failure, hypertension, age ≥ 75 years (2 points), diabetes mellitus, 
previous stroke or TIA (2 points), vascular disease, age 65-74 years and sex class 
(female)) score [3] has become widely used for the stratification of stroke and 
thromboembolic risk. 
Stroke risk stratification in non-AF patients has been less intensively studied. 
Recently, we and others showed that the CHA2DS2VASc score and the Essen Stroke 
Risk Score (1 point for each of age 65-75 years, age above 75 years (2 points), 
hypertension, diabetes, myocardial infarction (MI), other cardiovascular disease 
(except MI and AF), peripheral arterial disease, smoking and previous stroke or TIA) 
perform only modestly for predicting the risk of recurrent ischemic stroke in non-AF 
patients [4,5]. Hence, it is of interest to consider alternative parameters that can 
improve upon these stroke risk stratification schemes. 
Studies on cerebral white matter hyperintensities and the risk of recurrent stroke have 
shown varying results. Some studies found no association [7,8] whereas a number of 
newer studies have found an association between white matter hyperintensities and 
an increased risk of recurrent stroke [9–12], as well as a poorer prognosis after 
ischemic stroke [13–15]. Thus, the severity of white matter hyperintensities may hold 
important information to aid risk stratification for recurrent ischemic stroke. 
In the present study, we used observational data from Danish patient registries to 
investigate whether the severity of white matter hyperintensities was associated with 
the risk of ischemic stroke recurrence, death, and cardiovascular events in a non-AF 
cohort of patients with incident ischemic stroke. Second, we investigated the 
predictive performance of the CHA2DS2VASc score and the Essen Stroke Risk Score 
when augmented with information on white matter hyperintensities. 
Methods 
Data Sources 
The study was based on brain imaging studies from two Danish hospitals, The Danish 
Stroke Registry, and Danish national registries. The Danish Stroke Registry was 
established in 2003 and holds information on diagnosis and various clinical variables 
such as selected comorbidities, smoking habits and stroke severity on all Danish 
stroke patients [16]. Diagnoses in The Danish Stroke Registry rely on the best 
judgment of the treating physician based on the available information at the time of 
diagnosis (medical files, imaging, prescriptions, patients, or proxy self-report). The 
Danish National Patient Registry [17] has registered all hospital admissions in 
Denmark with corresponding discharge diagnoses since 1977. The National 
Prescription Registry [18] holds data on all prescriptions dispensed from Danish 
pharmacies since 1994, coded according to the Anatomic Therapeutic Chemical 
(ATC) Classification System. Lastly, The Danish Civil Registration System contains 
information on date of birth, sex, migration, and vital status of all citizens [19]. 
Study Population 
The study population consisted of all patients aged 18 years or above, registered in 
The Danish Stroke Registry with an incident ischemic stroke (International 
Classification of Diseases 10th revision (ICD-10) codes I63 or I64) (index stroke), 
and referred to Aalborg University Hospital or Hjørring Hospital, Denmark in the 
period between January 1, 2005 and December 31, 2012. Only patients who had 
undergone a brain MRI scan within four weeks after the index stroke were included. 
Patients with a history of AF were excluded.  
Data from the brain imaging studies and The Danish Stroke Registry were linked with 
information from The Danish National Patient Registry, The National Prescription 
Registry, and The Danish Civil Registration System via the unique personal 
identification number assigned to all Danish residents [19]. We calculated the 
CHA2DS2VASc score and the Essen Stroke Risk Score (clinical scores) based on the 
information in the registries (as previously described in detail [4,20]). Antithrombotic 
treatment was defined as initiation or continuation of antithrombotics (aspirin, 
clopidogrel and/or dipyridamole) during the admission for the index stroke. 
Neuroimaging 
Brain imaging was performed on 1.5 or 3.0 Tesla magnetic resonance imaging (MRI) 
scanners. The choice of MRI scanner depended only on the availability of the 
scanners. Analysis of the images was performed by a neurologist blinded to patient 
characteristics. To quantify the interobserver agreement a random sample of 50 
patients was also independently analyzed by a consultant neuroradiologist. 
White matter hyperintensities were assessed on T2-weigted and/or T2 fluid-
attenuated inversion recovery (FLAIR) images as hyperintense lesions, isointense on 
diffusion weighted images (DWI) [21]. The white matter hyperintensities were rated 
according to the Fazekas scale, and were categorized as deep white matter (DWMH) 
or periventricular (PVH) hyperintensities [22]. DWMH were rated as follows: 
0=absence, 1=punctate foci, 2=beginning confluence of foci, 3=large confluent areas. 
PVH were rated as follows: 0=absence, 1=”caps” or pencil-thin lining, 2=smooth 
“halo”, 3=irregular PVH extending into the deep white matter. PVH extending > 1 
cm into the adjacent white matter were considered to involve the deep white matter 
[23]. Hyperintensities in the deep grey nuclei and the brainstem were not rated. The 
total Fazekas score was calculated as the sum of DWMH and PVH, resulting in a 
score of 0-6. Acute ischemic infarcts were assessed as lesions hyperintense on DWI 
and hypointense on apparent diffusion coefficient (ADC) map. Lacunar infarction 
was defined as a round or ovoid DWI hyperintense lesion ≤ 20 mm situated in the 
cerebral hemispheric white matter, in the basal ganglia, or in the brain stem [24]. 
Outcomes 
The primary outcomes were recurrent ischemic stroke, death, and cardiovascular 
events. Cardiovascular events were defined as the composite of ischemic stroke 
(ICD-10 codes I63, I64), TIA (ICD-10 code G45), myocardial infarction (ICD-10 
codes I21, I23) or arterial thromboembolism (ICD-10 code I74). Diagnoses of 
recurrent ischemic stroke were identified in The Danish Stroke Registry and all other 
diagnoses were identified in The Danish National Patient Registry. Patients were 
followed from the day of the index stroke and until the outcome event under study, 
death, emigration, or end of study (December 31, 2013), whichever came first. 
Statistical Analysis 
Continuous data were summarized as mean values and standard deviations and 
categorical data as counts and proportions. Event rates of recurrent stroke, death, and 
cardiovascular events were calculated and stratified by the DWMH score, the PVH 
score, the total Fazekas score, the CHA2DS2VASc score, and the Essen Stroke Risk 
Score. Unadjusted hazard ratios based on the Cox proportional hazard model were 
calculated for increasing values of the imaging scores and the clinical scores. In 
addition we calculated hazard ratios for increasing values of the neuroimaging scores 
adjusted for the components of the CHA2DS2VASc score. The reference was the 
lowest score on each scale: DWMH=0, PVH=1 (there were no patients with a score 
of 0), total Fazekas score=1, CHA2DS2VASc score=2 (since all patients were 
assigned two points for the index stroke), and Essen Stroke Risk Score=0. Due to the 
small size of the groups, patients with a CHA2DS2VASc score ≥ 6 were merged into 
a single stratum, and similarly patients with an Essen Stroke Risk Score ≥ 4 were 
merged into a single stratum. 
We combined the neuroimaging scores and the clinical scores to recalibrated clinical 
scores by adding 1 point to the CHA2DS2VASc score and the Essen Stroke Risk Score 
for a DWMH score ≥ 2. We performed sensitivity analyses for the recalibrated scores 
by applying different cutoffs of the DWMH score and the total Fazekas score: 
DWMH score = 3, total Fazekas score ≥ 4, and total Fazekas score = 6. The 
discriminatory performance of the neuroimaging scores, the clinical scores, and the 
recalibrated scores was assessed with the C-statistic [25]. Predictive power of the 
scores were based on Somers' D rank statistic transformed to Harrell's C for survival 
models [26]. A two-sided P-value less than 0.05 was considered statistically 
significant. Stata version 13 (Stata Corporation, College Station, TX) was used for 
statistical analysis. 
Ethics 
The study was approved by the Danish Data Protection Agency, file no. 2012-41-
0633. In Denmark, no ethical approval is required for anonymous registry studies. 
Results 
In The Danish Stroke Registry, we identified 3,751 patients ≥ 18 years admitted to 
Aalborg University Hospital or Hjørring Hospital with incident ischemic stroke in the 
period between January 1, 2005 and December 31, 2012. We excluded 652 patients 
with a diagnosis of AF. In 2,267 patients there was no available brain MRI. Hence, 
the study cohort consisted of 832 patients with incident ischemic stroke, no AF, and 
an available brain MRI. The patients not included in the study due to no available 
MRI were older (mean age 70.9 versus 59.6 years), had more severe strokes (mean 
SSS score 44.7 versus 49.8) and higher CHA2DS2VASc score (mean score 4.4 versus 
3.6). 
In the rating of the random sample of 50 MRI scans we found full agreement between 
the two raters in 74% (DWMH) and 80% (PVH) of the cases. In the remaining there 
was a disagreement of maximally 1 point. 
Baseline characteristics of the cohort are summarized in Table 1. Lacunar type infarct 
of the index stroke was found in 215 (25.9%) patients. During a mean follow-up time 
of 3.3 (SD 2.1) years, we observed 55 recurrent ischemic strokes, 80 deaths, and 102 
cardiovascular events. During the first year of follow-up, the overall annual rates of 
recurrent ischemic stroke, death, and cardiovascular events were 3.4%, 4.1% and 
7.4% respectively.  
Incidence rates for the outcomes stratified by the neuroimaging scores and the clinical 
scores are shown in Figure 1 and in Table S-1 in the online supplementary material. 
Incidence rates for all outcomes increased with increasing values of the scores. Cox 
proportional hazard ratios stratified by the neuroimaging scores, adjusted for the 
components of the CHA2DS2VASc score, are shown in Table 2. Increasing values of 
all scores were significantly associated with an increased rate of recurrent ischemic 
stroke. For the outcomes of death and cardiovascular events hazard ratios also showed 
an increasing trend. Unadjusted Cox hazard ratios stratified by the neuroimaging 
scores and the clinical scores are shown in Table S-2 in the online supplementary 
material. 
Overall, the discriminatory performance of the scores was modest with C-statistics 
around 0.60-0.70 as shown in Table 3. When recalibrating the CHA2DS2VASc score 
and the Essen Stroke Risk Score by adding a point for a DWMH score ≥ 2, the 
discriminatory performance in terms of C-statistics was improved (Table 3). For the 
outcome of recurrent ischemic stroke these improvements were statistically 
significant (the recalibrated CHA2DS2VASc score versus the CHA2DS2VASc score: 
p=0.024; the recalibrated Essen Stroke Risk Score versus the Essen Stroke Risk 
Score: p=0.031). For the outcomes of death and cardiovascular events, the differences 
were not statistically significant. 
The C-statistic for the prediction of ischemic stroke recurrence was numerically 
highest for the DWMH score and the total Fazekas score (around 0.65). These values 
were not significantly higher than those of the clinical scores (the DWMH score 
versus the CHA2DS2VASc score: p=0.13, versus the Essen Stroke Risk Score: 
p=0.25; the total Fazekas score versus the CHA2DS2VASc score: p=0.11, versus the 
Essen Stroke Risk Score: p=0.23). Neither was there any statistically significant 
differences between the C-statistics of the neuroimaging scores and the clinical scores 
for the outcomes death and cardiovascular events. 
Sensitivity analyses 
In the sensitivity analyses of the recalibrated scores with cutoffs of DWMH score = 
3, total Fazekas score ≥ 4, and total Fazekas score = 6, the C-statistics for ischemic 
stroke recurrence were comparable to the analyses with a cutoff of DWMH ≥ 2 
(around 0.61) (data not shown). For the cutoff of the total Fazekas score ≥ 4, the C-
statistics for ischemic stroke recurrence were significantly higher for the recalibrated 
scores compared to the original scores. For the cutoffs of DWMH = 3 and total 
Fazekas score = 6 the C-statistics of the recalibrated scores were not significantly 
different from those of the original scores. 
Discussion 
In the present study, our principal finding was that an increasing burden of white 
matter hyperintensities is associated with the risk of recurrent ischemic stroke in non-
AF patients, even after adjusting for known stroke risk factors. Second, the 
combination of information on white matter hyperintensities with the 
CHA2DS2VASc score and the Essen Stroke Risk Score improved the discriminatory 
performance of these clinical scores. 
This study confirms prior research showing that cerebral white matter 
hyperintensities are associated with an increased risk of recurrent stroke in ischemic 
stroke patients [9–12]. For the first time, we report that an increasing burden of 
periventricular and deep white matter hyperintensities, as well the total Fazekas score, 
are associated with an increasing risk of recurrent ischemic stroke after adjusting for 
known clinical stroke risk factors. This dose-response association has not been clearly 
demonstrated previously and it emphasizes that the burden of white matter 
hyperintensities holds important prognostic information. Previous studies indicate 
that the association between white matter hyperintensities and the clinical outcomes 
may be weaker among stroke patients with AF [10,12], hence, our finding may have 
been strengthened by the fact that the present study included only non-AF patients. 
We have previously shown that the CHA2DS2VASc score and the Essen Stroke Risk 
Score by themselves perform only modestly in the prediction of ischemic stroke 
recurrence in a nationwide non-AF ischemic stroke cohort [4]. The present study 
reveals a potential for improving these scores by adding information on white matter 
hyperintensities. Virtually all stroke patients undergo neuroimaging and therefore, 
these findings are valuable in the efforts to develop improved clinical risk 
stratification schemes based on readily accessible parameters. 
Our findings are in contrast to the results of a recent study from the Athens Stroke 
Registry [12]. In this study, adding one point for leukoaraiosis on brain CT or MRI 
to the CHADS2 (congestive heart failure, hypertension, age ≥75 years, diabetes 
mellitus, previous stroke or TIA (2 points)) and the CHA2DS2VASc score in AF and 
non-AF ischemic stroke patients did not increase the accuracy of these scores in 
stroke recurrence prediction. However, the discrepancies between the Greek study 
and our study may be explained by differences in the applied imaging modalities and 
the thresholds chosen to define the presence of white matter hyperintensities or 
leukoaraiosis. First, we included only patients who had undergone MRI, whereas in 
the Greek study, both CT and MRI were allowed. Second, as we have demonstrated, 
choosing cutoffs equal to moderate severity of the white matter hyperintensities (a 
DWMH score ≥ 2 and a total Fazekas score ≥ 4) resulted in an improved 
discriminatory performance of the recalibrated CHA2DS2VASc score and the 
recalibrated Essen Stroke Risk Score. On the other hand, choosing cutoffs that 
included only the most severe changes (a DWMH score = 3 and a total Fazekas score 
= 6) did not lead to a significantly improved predictive ability of the recalibrated 
clinical scores. In the Greek study, the definition of leukoaraiosis was probably 
reserved for relatively widespread changes and further, they applied a different 
neuroimaging rating scale. 
We found that for the prediction of recurrent ischemic stroke, white matter 
hyperintensities burden alone performed on par with both the original clinical scores 
and the recalibrated clinical scores. Risk factors for white matter hyperintensities, 
namely age and hypertension, and less well documented, diabetes [27], are comprised 
in the clinical scores. Thus, it can be argued that white matter hyperintensities are just 
an intermediate in the chain of cause and effect in the development of ischemic stroke 
[28]. However, the extent of white matter hyperintensities may indicate the individual 
cerebral susceptibly to these risk factors and therefore white matter hyperintensities 
may be a more disease specific marker for the risk of stroke recurrence among non-
AF stroke patients. Consistent with this interpretation, the original clinical risk scores 
performed better than white matter hyperintensities for predicting death and 
cardiovascular events. 
Strengths and limitations 
The main strengths of our study are the relatively large size of the cohort, the 
completeness of the follow-up, and the application of MRI for the assessment of the 
cerebral changes. There are also several important limitations. First, since this was a 
register-based study, we cannot exclude misclassification of both the stroke diagnosis 
and comorbidities, although the validity of the stroke diagnosis in the Danish Stroke 
Registry has previously been shown to be high [29]. Second, we only included 
patients with an MRI scan. These patients were generally younger and healthier than 
patients without an MRI scan, and this selective inclusion may limit the 
generalizability of our findings. Third, MRI scans were rated by one neurologist only. 
Although a small validation sample was also rated by a consultant neuroradiologist 
and reproducibility was deemed acceptable, we cannot rule out rater bias. 
In conclusion, increasing burden of white matter hyperintensities was independently 
associated with the risk of recurrent ischemic stroke after adjusting for risk factors 
within the CHA2DS2VASc score. Recalibration of the CHA2DS2VASc score and the 
Essen Stroke Risk Score with information on white matter hyperintensities led to 
improved discriminatory performance of these scores in ischemic stroke recurrence 
prediction. Risk scores based on white matter hyperintensities alone were at least as 
accurate as established clinical risk scores in the prediction of recurrent ischemic 
stroke. 
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Table 1. Baseline characteristics (n=832) 
Demographics 
Age, years 59.6 (13.9) 
Age > 65 years 307 (36.9) 
Age > 75 years 120 (14.4) 
Female sex 349 (42.0) 
Risk factors 
Congestive heart failure 9 (1.1) 
Hypertension 396 (47.6) 
Diabetes 76 (9.1) 
Previous TIA 46 (5.5) 
Vascular disease 74 (8.9) 
Previous myocardial infarction 21 (2.5) 
Peripheral arterial disease 38 (4.6) 
Other heart disease 32 (3.9) 
Smoking (current or previous) 505 (60.7) 
CHA2DS2VASc score 3.6 (1.3) 
Essen Stroke Risk Score 1.9 (1.4) 
Antithrombotic treatment 784 (94.3) 
DWMH score 
0 311 (37.4) 
1 292 (35.1) 
2 150 (18.0) 
3 79 (9.5) 
PVH score 
0 0 (0.0) 
1 525 (63.1) 
2 192 (23.1) 
 3 115 (13.8) 
Total Fazekas score 
0 0 (0.0) 
1 307 (39.9) 
2 211 (25.4) 
3 94 (11.3) 
4 106 (12.7) 
5 36 (4.3) 
6 78 (9.4) 
Abbreviations: TIA = transient ischemic attack; CHA2DS2VASc = congestive heart failure, 
hypertension, age ≥ 75 years (2 points), diabetes mellitus, previous stroke or transient ischemic 
attack (2 points), vascular disease, age 65-74 years and sex class (female); DWMH: deep white 
matter hyperintensities; PVH: periventricular hyperintensities; DWI: diffusion weighted 
images. 
Data are mean (SD) or n (%) 
Table 2. Adjusted Cox proportional hazard analysis showing stratified hazard ratios 
of recurrent ischemic stroke, death, and cardiovascular events.  
Adjusted hazard ratio (95% CI) 
Recurrent ischemic 
stroke 
Death Cardiovascular events 
DWMH score 
0 1.00 (reference) 1.00 (reference) 1.00 (reference) 
1 1.93 (0.89-4.18) 1.59 (0.80-3.16) 1.21 (0.72-2.03) 
2 3.08 (1.35-7.02) 1.38 (0.64-3.00) 1.57 (0.88-2.83) 
3 4.99 (1.88-13.22) 2.17 (0.97-4.89) 2.08 (1.02-4.24) 
PVH score 
1 1.00 (reference) 1.00 (reference) 1.00 (reference) 
2 2.00 (1.01-3.93) 1.79 (0.98-3.25) 1.37 (0.83-2.25) 
3 3.40 (1.58-7.33) 2.06 (1.09-3.90) 1.83 (1.02-3.28) 
Total Fazekas 
score 
1 1.00 (reference) 1.00 (reference) 1.00 (reference) 
2 1.65 (0.70-3.86) 1.45 (0.66-3.17) 1.28 (0.73-2.24) 
3 2.83 (1.10-7.27) 2.11 (0.92-4.82) 1.33 (0.65-2.69) 
4 2.77 (1.12-6.88) 1.70 (0.72-3.99) 1.57 (0.81-3.02) 
5 4.08 (1.32-13.52) 1.75 (0.58-5.25) 1.85 (0.74-4.66) 
6 5.28 (1.98-14.07) 2.54 (1.10-5.83) 2.20 (1.07-4.53) 
Analyses were adjusted for the components of the CHA2DS2VASc score. Cardiovascular 
events represent the composite endpoint of ischemic stroke, transient ischemic attack, 
myocardial infarction, or arterial thromboembolism. Abbreviations:  DWMH = deep white 
matter hyperintensities; PVH = periventricular hyperintensities; CHA2DS2VASc = congestive 
heart failure, hypertension, age ≥ 75 years (2 points), diabetes mellitus, previous stroke or 
transient ischemic attack (2 points), vascular disease, age 65-74 years and sex class (female).  
Table 3. C-statistics for the clinical scores, the combination of the clinical scores 
and a DWMH score ≥ 2, and the neuroimaging scores. 
Score 
Recurrent 
ischemic stroke 
Death 
Cardiovascular 
events 
CHA2DS2VASc score 0.59 (0.51-0.65) 0.70 (0.64-0.77) 0.59 (0.54-0.65) 
Essen Stroke Risk Score 0.60 (0.53-0.68) 0.69 (0.62-0.76) 0.60 (0.55-0.65) 
CHA2DS2VASc score + 
DWMH score ≥2 
0.62 (0.54-0.70) 0.72 (0.66-0.78) 0.61 (0.56-0.67) 
Essen Stroke Risk Score + 
DWMH score ≥2 
0.63 (0.56-0.71) 0.71 (0.65-0.77) 0.62 (0.57-0.67) 
DWMH score 0.65 (0.58-0.73) 0.65 (0.66-0.78) 0.59 (0.54-0.65) 
PVH score 0.62 (0.52-0.68) 0.66 (0.61-0.72) 0.58 (0.53-0.63) 
Total Fazekas score 0.65 (0.58-0.73) 0.67 (0.61-0.73) 0.60 (0.54-0.65) 
One point was added to the CHA2DS2VASc score and the Essen Stroke Risk Score for a 
DWMH score ≥2. Cardiovascular events represent the composite endpoint of ischemic stroke, 
transient ischemic attack, myocardial infarction, or arterial thromboembolism. Abbreviations: 
CHA2DS2VASc = congestive heart failure, hypertension, age ≥ 75 years (2 points), diabetes 
mellitus, previous stroke or transient ischemic attack (2 points), vascular disease, age 65-74 
years and sex class (female); DWMH = deep white matter hyperintensity; PVH = 
periventricular hyperintensity. Data are C-statistics (95% CI). 
Figure 1. Annual rates of recurrent ischemic stroke, death, and cardiovascular 
events per 100 person-years 
The analyses were stratified by the DWMH score (A), the PVH score (B), the Total Fazekas 
score (C), the CHA2DS2VASc score (D), and the Essen Stroke Risk Score (E). 
Cardiovascular events represent the composite endpoint of ischemic stroke, transient ischemic 
attack, myocardial infarction, or arterial thromboembolism. Abbreviations:  DWMH = deep 
white matter hyperintensities; PVH = periventricular hyperintensities; CHA2DS2VASc = 
congestive heart failure, hypertension, age ≥ 75 years (2 points), diabetes mellitus, previous 
stroke or transient ischemic attack (2 points), vascular disease, age 65-74 years and sex class 
(female). 
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Table S-1. Event rates per 100 person-years according to levels of the risk scores. 
Recurrent ischemic 
stroke 
Death 
Cardiovascular 
events 
DWMH score 
0 11 1.0 13 1.1 28 2.6 
1 18 1.9 28 2.8 34 3.7 
2 16 3.4 18 3.5 25 5.4 
3 10 4.8 21 9.3 15 7.4 
PVH score 
0 0 0.0 0 0.0 0 0.0 
1 24 1.3 26 1.4 52 2.9 
2 17 2.9 27 4.3 29 5.1 
3 14 4.3 27 7.6 21 6.6 
Total Fazekas 
score 
1 11 1.0 12 1.0 27 2.5 
2 11 1.6 14 1.9 24 3.5 
3 9 3.1 15 4.7 13 4.6 
4 10 3.0 13 3.7 17 5.3 
5 4 3.4 5 4.0 6 5.3 
6 10 4.9 21 9.4 15 7.5 
CHA2DS2VASc 
score 
2 8 1.3 7 1.1 12 1.9 
3 14 1.4 15 1.5 30 3.2 
4 16 2.5 16 2.3 25 4.0 
5 11 3.2 21 5.8 19 5.7 
≥6 6 3.8 21 11.9 11 7.3 
Essen Stroke 
Risk Score 
0 3 0.7 5 1.1 5 1.2 
1 17 1.7 14 1.3 29 3.0 
2 13 1.8 15 2.0 28 4.1 
3 11 3.1 17 4.4 19 5.7 
≥4 11 4.3 29 10.5 16 6.4 
Cardiovascular events represent the composite endpoint of ischemic stroke, transient ischemic 
attack, myocardial infarction, or arterial thromboembolism. Abbreviations:  DWMH = deep 
white matter hyperintensities; PVH = periventricular hyperintensities; CHA2DS2VASc = 
congestive heart failure, hypertension, age ≥ 75 years (2 points), diabetes mellitus, previous 
stroke or transient ischemic attack (2 points), vascular disease, age 65-74 years and sex class 
(female). 
Table S-2. Unadjusted Cox proportional hazard analysis showing hazard ratios of 
recurrent ischemic stroke, death, and cardiovascular events. 
Hazard ratio (95% CI) 
Recurrent ischemic 
stroke 
Death Cardiovascular events 
DWMH score 
0 1.00 (reference) 1.00 (reference) 1.00 (reference) 
1 1.86 (0.88-3.95) 2.42 (1.25-4.66) 1.39 (0.84-2.29) 
2 3.33 (1.54-7.18) 3.08 (1.51-6.28) 2.02 (1.18-3.47) 
3 4.48 (1.90-10.57) 7.77 (3.88-15.55) 2.56 (1.36-4.79) 
PVH score 
1 1.00 (reference) 1.00 (reference) 1.00 (reference) 
2 2.17 (1.16-4.04) 3.10 (1.81-5.31) 1.70 (1.08-2.68) 
3 3.11 (1.61-6.02) 5.42 (3.16-9.30) 2.11 (1.27-3.51) 
Total Fazekas 
score 
1 1.00 (reference) 1.00 (reference) 1.00 (reference) 
2 1.53 (0.66-3.54) 1.77 (0.82-3.84) 1.37 (0.79-2.38) 
3 3.00 (1.24-7.24) 4.42 (2.07-9.44) 1.77 (0.91-3.43) 
4 2.95 (1.25-6.95) 3.43 (1.56-7.52) 2.02 (1.10-3.70) 
5 3.39 (1.08-10.64) 3.78 (1.33-10.72) 2.08 (0.86-5.03) 
6 4.50 (1.91-10.61) 8.45 (4.15-17.21) 2.67 (1.42-5.02) 
CHA2DS2VASc 
2 1.00 (reference) 1.00 (reference) 1.00 (reference) 
3 1.12 (0.47-2.68) 1.39 (0.57-3.41) 1.68 (0.87-3.28) 
4 1.91 (0.82-4.45) 2.10 (0.87-5.12) 2.01 (1.01-4.00) 
5 2.30 (0.92-5.73) 5.15 (2.18-12.12) 2.96 (1.46-6.02) 
≥6 2.53 (0.87-7.32) 10.25 (4.34-24.20) 3.62 (1.65-7.97) 
Essen Stroke Risk 
Score 
0 1.00 (reference) 1.00 (reference) 1.00 (reference) 
1 2.48 (0.73-8.48) 1.20 (0.43-3.34) 2.65 (1.03-6.84) 
2 2.56 (0.73-8.98) 1.77 (0.64-4.87) 3.42 (1.32-8.85) 
3 4.17 (1.16-14.99) 3.76 (1.39-10.20) 4.83 (1.82-12.83) 
≥4 5.50 (1.53-19.75) 8.64 (3.34-22.37) 5.27 (1.95-14.20) 
The analyses were stratified by the neuroimaging and the clinical scores. Cardiovascular events 
represent the composite endpoint of ischemic stroke, transient ischemic attack, myocardial 
infarction, or arterial thromboembolism. Abbreviations:  DWMH = deep white matter 
hyperintensities; PVH = periventricular hyperintensities. 
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ischemic stroke.  Results: In 81 (10.3%) patients, a single si-
lent lacune was present, and in 87 (11.1%) patients, multiple 
silent lacunes were present. Patients with at least one silent 
lacune were older (mean age 66.1 vs. 57.7, p < 0.001) and 
were more often hypertensive (60.1 vs. 43.4%, p < 0.001) 
compared to patients with no silent lacunes. During a me-
dian follow-up time of 2.9 (interquartile range 3.1) years, we 
observed 53 recurrent ischemic strokes, 76 deaths, and 96 
cardiovascular events. Incidence rates per 100 person-years 
of ischemic stroke recurrence were 1.6, 2.5, and 5.0 for none, 
single, and multiple silent lacunes respectively. Correspond-
ing incidence rates were 2.6, 2.4, and 4.4 for death, and 3.4, 
4.0, and 6.6 for cardiovascular events respectively. Adjusted 
HRs of ischemic stroke recurrence were 1.53 (0.67–3.49) and 
2.52 (1.25–5.09) for a single and multiple silent lacunes, re-
spectively. Further adjustment for white matter hyperinten-
sities maintained positive association although not signifi-
cant. Corresponding adjusted HRs were 0.56 (0.25–1.25) and 
0.65 (0.33–1.25) for death and 1.16 (0.61–2.22) and 1.51 
(0.86–2.66) for cardiovascular events.  Conclusions: In this 
large cohort of patients with incident ischemic stroke and no 
AF, an increasing number of silent lacunes was associated 
with increasing incidence rates of ischemic stroke recur-
 Key Words 
 Ischemic stroke · Lacunar stroke · Cerebral small vessel 
disease · MRI · Prognosis 
 Abstract 
 Background: Silent lacunes are a common finding on brain 
imaging in ischemic stroke patients, but the prognostic sig-
nificance of these lesions is uncertain. We aimed at investi-
gating the association of silent lacunes and the risk of isch-
emic stroke recurrence, death, and cardiovascular events in 
a cohort of patients with incident ischemic stroke and no 
atrial fibrillation (AF).  Methods: We included 786 patients 
(mean age 59.5 (SD 14.0); 42.9% females) in a registry-based, 
observational cohort study on patients with first-ever isch-
emic stroke. On brain MRI we assessed the number of silent 
lacunes as none, single, or multiple and we calculated strati-
fied incidence rates of the outcomes. Cox proportional haz-
ard ratios (HRs) adjusted for age, gender, congestive heart 
failure, hypertension, diabetes, and vascular disease were 
calculated with no silent lacunes as reference. In additional 
analyses, we further adjusted for white matter hyperintensi-
ties. Patients were followed up until death or recurrence of 
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rence. In the adjusted Cox proportional hazard analyses, the 
presence of multiple silent lacunes was significantly associ-
ated with an increased risk of ischemic stroke recurrence. 
The risk of death or cardiovascular events was not signifi-
cantly influenced by the presence of silent lacunes. 
 © 2016 S. Karger AG, Basel 
 Introduction 
 Lacunes are small fluid-filled cavities in the subcortical 
and deep regions of the brain, resulting from an ischemic 
infarct, or in rare cases a small hemorrhage  [1] . Silent la-
cunes are similar lesions but without preceding corre-
sponding clinical symptoms. Most knowledge on the 
prognostic significance of silent lacunes comes from 
studies on silent brain infarcts. There exists no univer-
sally accepted definition of silent brain infarcts, though 
most studies have included silent lacunes as well as corti-
cal and territorial infarcts. In the Rotterdam Scan Study, 
lacunes constituted 95% of silent brain infarcts  [2] ; hence, 
the findings from studies on silent brain infarcts may 
largely apply to silent lacunes.
 The prevalence of silent brain infarcts in population-
based studies ranges from 8%  [3] to 28%  [4] and is strong-
ly dependent on age  [5] . In population-based cohorts in 
patients without symptomatic cerebrovascular disease, 
several studies have demonstrated silent brain infarcts to 
be a risk factor for future stroke  [6–8] .
 In ischemic stroke patients, the prevalence of silent 
brain infarcts is also age dependent  [9], but the prog-
nostic significance is more ambiguous. Older studies 
did not find higher risk of mortality in stroke patients 
with silent brain infarcts, but these studies did not in-
vestigate the risk of stroke recurrence  [9–11] . In a minor 
study of patients with lacunar stroke, silent lacunar in-
farcts increased the risk of stroke recurrence as well as 
the risk of mortality  [12] , and in a recent Finnish study 
of young stroke patients (15–49 years), the presence of 
multiple, but not a single, silent brain infarcts was as-
sociated with an increased risk of stroke recurrence but 
not with neither mortality nor a composite vascular 
endpoint  [13] . In a subgroup analysis from the  PRoFESS 
trial  [14] , a cohort of patients with non-cardioembolic 
ischemic stroke, silent brain infarcts were not signifi-
cantly associated with neither recurrent stroke nor 
death  [15] . Hence, the prognostic significance of silent 
brain infarcts in ischemic stroke patients is still debat-
able. Further, a majority of previous studies did not dis-
criminate between the presence of a single or multiple 
silent brain infarcts. As shown in the study by Putaala 
et al.  [13], the number of silent brain infarcts may carry 
important prognostic information. This information 
may be of value in future clinical stroke risk–stratifica-
tion models.
 In this study, we aimed at investigating the association 
of the number of silent lacunes with recurrent ischemic 
stroke, death, and cardiovascular events in a cohort of pa-
tients with incident ischemic stroke and no atrial fibrilla-
tion (AF). We hypothesized a stepwise positive correla-
tion between the number of silent lacunes (categorized as 
none, single, or multiple) and stroke, death, and cardio-
vascular events.
 Methods 
 Data Sources 
 We conducted a registry-based study on data from the Danish 
Stroke Registry, Danish national registries, and brain imaging 
studies from 2 Danish hospitals. The Danish Stroke Registry was 
founded in 2003, and it is mandatory for all Danish hospital de-
partments treating stroke patients to report a standardized set of 
data to the registry. We have previously described the registry in 
details  [16] . Diagnoses in the Danish Stroke Registry rely on the 
best judgment of the treating physician based on the available in-
formation at the time of diagnosis (medical files, imaging, pre-
scriptions, patients, or proxy self-report). The sensitivity and the 
positive predictive value of a stroke diagnosis in the Danish Stroke 
Registry is  ≥ 90%  [17] . The Danish National Patient Registry  [18] 
has registered all hospital admissions in Denmark with corre-
sponding discharge diagnoses since 1977. Up to 1993, all diagnoses 
were coded according to the 8th revision of the International Clas-
sification of Diseases (ICD-8), and since 1994, all diagnoses are 
coded according to the ICD-10. The National Prescription Regis-
try  [19] keeps data on all prescriptions dispensed from Danish 
pharmacies since 1994, coded according to the Anatomic Thera-
peutic Chemical Classification System. The Danish Civil Registra-
tion System holds information on date of birth, gender, migration, 
and vital status of all citizens  [20] . Information from the registries 
was linked using the unique personal registration number assigned 
to all Danish residents  [20] .
 Study Population 
 The study population comprised all patients aged 18 years or 
above, registered in the Danish Stroke Registry with an incident 
ischemic stroke (ICD-10 codes I63 or I64; index stroke), and 
referred to Aalborg University Hospital or Hjørring Hospital, 
Denmark in the period between January 1, 2005 and December 
31, 2012. We excluded patients with a history of AF, patients 
with a previous transient ischemic attack (TIA), and patients in 
whom no MRI had been performed within 6 weeks after the in-
dex stroke. See online supplementary material (for all online 
suppl. material, see www.karger.com/doi/10.1159/000445196) 
for the applied definitions of AF and TIA. Patients with previous 
TIA were excluded to assure that the observed silent lacunes 
were truly silent.
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 Comorbidity and Medication 
 Estimated glomerular filtration rate (eGFR) was calculated 
from a single creatinine measurement based on the Modification 
of Diet in Renal Disease-formula  [21] . Antiplatelets comprised as-
pirin, clopidogrel, and dipyridamole and anticoagulants com-
prised warfarin, phenprocoumon, dabigatran, apixaban, and riva-
roxaban. Antiplatelet use and anticoagulant use was defined as 
continuation or initiation of any of the defined drugs during the 
admission or a redeemed prescription of any of the defined drugs 
less than 30 days after the discharge. Statin use was defined as a 
redeemed prescription of any statin in the period from 90 days be-
fore until 30 days after the index stroke. For the applied definitions 
of congestive heart failure, hypertension, diabetes, vascular dis-
ease, and smoking refer to the online suppl. material.
 Neuroimaging 
 Brain imaging was performed on 1.5 or 3.0 Tesla MRI scanners. 
A stroke neurologist blinded to patient characteristics performed 
brain imaging analysis. To quantify the reproducibility of the im-
age analysis, we assessed a kappa value of interobserver agreement 
based on a random sample of 50 patients who were also indepen-
dently analyzed by a consultant neuroradiologist.
 Silent lacunes were considered round or ovoid well-defined 
areas of 3–15 mm in the territory of one perforating arteriole 
(hemispheric white matter, basal ganglia, brainstem or cerebel-
lum) with signal characteristics similar to cerebrospinal fluid: hy-
pointense on fluid-attenuated inversion recovery (FLAIR) and 
T1-weighted images and hyperintense on T2-weighted images 
 [1] . In some patients, only T1-weighted or T2-weighted images 
were available. Lesions in the size  ≤ 2 mm and with signal charac-
teristics similar to lacunes were considered perivascular spaces 
 [1] . The number of silent lacunes was classified as none, single, or 
multiple silent lacunes. White matter hyperintensities were as-
sessed on T2-weighted and/or T2 FLAIR images as hyperintense 
lesions, isointense on diffusion weighted images (DWIs). The 
white matter hyperintensities were rated according to the Fazekas 
scale resulting in a score of 0–6  [22] and graded as none to mild 
(Fazekas score  ≤ 2), moderate (Fazekas score 3–4) or severe (Faze-
kas score  ≥ 5).
 Acute ischemic infarcts were assessed as hyperintense lesions 
on DWI and hypointense on apparent diffusion coefficient map, 
and the location was classified as follows: anterior circulation 
(lesion(s) confined to one anterior circulation territory), posterior 
circulation, basal ganglia (lesion(s) confined to deep grey nuclei), 
>1 vascular territory, or no visible DWI lesion. Lacunar infarction 
was defined as a round or ovoid DWI hyperintense lesion  ≤ 20 mm 
situated in the cerebral hemispheric white matter, in the basal gan-
glia, or in the brain stem  [23] .
 Outcomes 
 The primary outcomes were recurrent ischemic stroke, death, 
and cardiovascular events. Recurrent ischemic stroke was identi-
fied in the Danish Stroke Registry as the first recurrence of isch-
emic stroke (ICD-10 codes I63, I64) after the index event. Cardio-
vascular events were defined as the composite of ischemic stroke, 
TIA (ICD-10 code G45), myocardial infarction (ICD-10 codes I21, 
I23) or arterial thromboembolism (ICD-10 code I74). Patients 
were followed from the day of the index stroke and until the out-
come event under study, death, emigration, or end of study 
( December 31, 2013), whichever came first.
 Statistical Analysis 
 Baseline continuous data were summarized using the mean 
and SD and categorical data by count and proportion. Continuous 
variables were compared with the Student’s t test and categorical 
variables were compared with the Fisher’s exact test. We calculated 
Goodman and Kruskal’s gamma for the association between silent 
lacunes and white matter hyperintensities. Event rates per 100 per-
son-years of recurrent ischemic stroke, death, and cardiovascular 
events were calculated for the whole cohort and stratified by the 
number of silent lacunes. Crude hazard ratios (HRs) based on the 
Cox proportional hazards model were calculated for an increasing 
number of silent lacunes with no silent lacunes as a reference. Ad-
justed HRs were adjusted for potential confounding effects of age, 
gender, congestive heart failure, hypertension, diabetes and vascu-
lar disease (model 1). In an additional model (model 2), we further 
adjusted for white matter hyperintensities. The effect of age was 
represented by a restricted cubic spline. The cumulative risk of re-
current stroke, death and cardiovascular events were calculated 
using the Kaplan–Meier estimator. Stata version 14 (Stata Corpo-
ration, College Station, Tex., USA) was used for the statistical anal-
yses. A two-sided p value <0.05 was considered statistically sig-
nificant.
 Ethics 
 The study was approved by the Danish Data Protection Agen-
cy, file No. 2012-41-0633. In Denmark, no ethical approval is re-
quired for anonymous registry studies.
 Results 
 In the Danish Stroke Registry, we identified 3,751 pa-
tients  ≥ 18 years with incident ischemic stroke admitted 
to the 2 hospitals in the period between January 1, 2005 
and December 31, 2012. We excluded 652 patients with 
AF and 135 patients with a previous TIA. In 2,178 pa-
tients, there was no available MRI scan from the acute 
phase of the index stroke; hence, 786 patients with inci-
dent ischemic stroke, no AF, and no previous TIA were 
included in the study cohort. The patients who did not 
undergo an MRI scan were older (mean age 70.9 vs. 
59.5) and had more severe strokes (mean Scandinavian 
Stroke Scale (SSS) score 44.7 vs. 49.9) than the patients 
included in the study cohort.
 The median time from hospital admission to MRI was 
1.8 (interquartile range 2.5) days. Inter-rater agreement 
in the identification of silent lacunes in the sample of 50 
MRI scans rated by 2 raters was found to be 98%, which 
equals a kappa value of 0.92.
 Baseline characteristics of the study cohort are shown 
in  table 1 . In 168 (21.5%) patients, at least one silent la-
cune was present, and in 87 (11.1%) patients, multiple 
silent lacunes were found. The prevalence of silent lacu-
nes increased markedly with increasing age as seen from 
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 figure 1 . Comparisons of patients with no silent lacunes 
and patients with at least one silent lacune are shown in 
 table 2 . Patients with at least one silent lacune were older, 
more often male and had a higher prevalence of conges-
tive heart failure, hypertension, reduced renal function, 
and moderate to severe white matter hyperintensities. 
Goodman and Kruskal’s gamma for the association be-
tween silent lacunes and white matter hyperintensities 
was 0.695. Lacunar infarction was more common among 
those with at least one silent lacune. There were no differ-
ences in stroke severity at presentation.
 During a median follow-up time of 2.9 (interquartile 
range 3.1) years there were 53 recurrent ischemic strokes, 
76 deaths, and 96 cardiovascular events (53 ischemic 
strokes, 29 TIAs, 12 myocardial infarctions, and 2 cases 
of arterial thromboembolism). No patients were lost to 
follow-up. We observed increasing rates of all the out-
comes for an increasing number of silent lacunes ( ta-
ble 3 ), except for the outcome of death and the presence 
of a single silent lacune, where we found a slightly lower 
rate compared to no silent lacunes. The cumulative risks 
of the outcomes based on the Kaplan–Meier method are 
shown in  figure 2 . The crude HRs were increasing for an 
increasing number of silent lacunes as shown in  table 3 , 
again with the exception of the outcome of death and a 
single silent lacune. In the Cox proportional hazards 
analyses adjusted for stroke risk factors (model 1), the 
HRs for recurrent ischemic stroke and cardiovascular 
Table 1.  Baseline characteristics (n = 786)
Demographics
Age, years, mean (SD) 59.5 (14.0)
Female gender 337 (42.9)
Risk factors
Congestive heart failure 9 (1.2)
Hypertension 369 (47.0)
Diabetes 73 (9.3)
Vascular disease 64 (8.14)
Smoking (current or previous) 468 (59.5)
Alcohol overuse 73 (9.29)
eGFR <45 ml/min/1.73 m2 31 (3.9)
Medication
Antiplatelets 754 (95.9)
Anticoagulants 28 (3.6)
Statins 433 (55.1)
Stroke severity
SSS, mean (SD) 49.9 (11.4)
Mild, SSS score 43–58 648 (82.8)
Moderate, SSS score 26–42 96 (12.2)
Severe, SSS score ≤25 39 (5.0)
Lacunar type infarction 203 (25.8)
Number of silent lacunes
0 618 (78.6)
1 81 (10.3)
≥2 87 (11.1)
White matter hyperintensities
Mild 495 (63.0)
Moderate 185 (23.5)
Severe 106 (13.5)
Infarct location
Anterior circulation 296 (37.7)
Posterior circulation 196 (24.9)
Basal ganglia 86 (10.9)
More than one vascular territory 75 (9.5)
Undetermined 133 (16.9)
 Data are n (%) if not otherwise indicated. SSS = Scandinavian Stroke Scale.
Table 2.  Baseline comparisons of patients with and without silent 
lacunes
No silent 
lacunes 
(n = 618)
≥1 silent 
lacunes 
(n = 168)
p value
Age, years, mean (SD) 57.7 (13.7) 66.1 (12.9) <0.001
Female gender 278 (45.0) 59 (35.1) 0.02
Congestive heart failure 4 (0.7) 5 (3.0) 0.03
Hypertension 268 (43.4) 101 (60.1) <0.001
Diabetes 51 (8.3) 22 (13.1) 0.07
Vascular disease 52 (8.4) 12 (7.1) 0.75
Smoking (current or previous) 364 (58.9) 104 (61.9) 0.54
eGFR <45 ml/min/1.73 m2 18 (2.9) 13 (7.7) 0.01
Moderate to severe stroke 107 (17.3) 28 (16.7) 0.91
Lacunar type infarction 143 (23.1) 60 (35.7) 0.001
Moderate to severe white
matter hyperintensities 170 (27.5) 121 (72.0) <0.001
 Data are n (%) if not otherwise indicated.
 Fig. 1. Age-specific prevalence of  ≥ 1 and  ≥ 2 silent lacunes. 
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events were increasing for an increasing number of si-
lent lacunes ( table 3 ), but this was significant only for the 
outcome of recurrent stroke. The risk of death or cardio-
vascular events was not significantly influenced by the 
presence of silent lacunes. In the analyses additionally 
adjusted for white matter hyperintensities (model 2), we 
observed similar associations, though the positive asso-
ciation between recurrent ischemic stroke and silent la-
cunes was insignificant in this model.
 Discussion 
 In the current study, we demonstrated that the pres-
ence of multiple silent lacunes was associated with an in-
creased risk of recurrent ischemic stroke in a cohort of 
non-AF patients with incident ischemic stroke. Second, 
neither the presence of a single nor multiple silent lacunes 
was significantly associated with the risk of risk death or 
cardiovascular events.
 A recent Finnish study investigated the prognostic sig-
nificance of silent brain infarcts in young stroke patients 
 [13] . They reported a significantly increased stroke recur-
rence risk in 15–49 years patients with multiple silent brain 
infarcts, without significant influence on either mortality 
or the composite vascular endpoint. Our results are in ac-
cordance with these findings, and we extended these re-
sults to comprise stroke patients of all ages, with the reser-
vation that our analyses were confined to silent lacunes.
 Lacunes are like white matter hyperintensities, a sign 
of cerebral small vessel disease  [24] . Previous studies have 
documented that an increasing burden of white matter 
 Fig. 2. Three-year cumulative risk of isch-
emic stroke recurrence ( a ), death ( b ), and 
cardiovascular events ( c ) stratified by the 
number of silent lacunes. 
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hyperintensities is associated with an increased risk of 
stroke recurrence  [25–27] . Since lacunes and white mat-
ter hyperintensities may be considered part of the same 
pathologic process, we are not surprised that increasing 
burdens of both these entities carry higher risk of stroke 
recurrence. We found that after further adjusting for 
white matter hyperintensities, the association between si-
lent lacunes and recurrent ischemic stroke was still posi-
tive although weaker and no longer statistically signifi-
cant. The weakening of the association was a result of the 
close correlation between silent lacunes and white matter 
hyperintensities. However, silent lacunes may still be a 
useful prognostic marker in models for stroke risk strati-
fication.
 In a recent study from Greece, it was shown that leu-
koaraiosis was associated with recurrent stroke in non-
AF patients but not in patients with AF  [28] . These find-
ings suggest a potential difference in the prognostic sig-
nificance of white matter hyperintensities in AF and 
non-AF related ischemic stroke. In the European Atrial 
Fibrillation Trial  [29] , which included patients with non-
rheumatic AF and a recent TIA or non-disabling isch-
emic stroke, patients with a silent brain infarct on CT did 
not have a higher risk of recurrent stroke compared to 
patients with symptomatic infarcts. In our study we in-
cluded only patients with no history of AF, and in the 
Finnish study by Putaala et al.  [13] only 2.9% of the pa-
tients had AF at baseline. Thus, these findings indicate 
that there may exist differences in the prognostic signifi-
cance of silent brain infarcts and silent lacunes in AF and 
non-AF patients, like in white matter hyperintensities. 
Future studies on prognosis of cerebral small vessel dis-
ease should take these considerations into account.
 The HRs for cardiovascular events also increased with 
an increasing number of silent lacunes, although not sta-
tistically significant. In part, this was caused by the effect 
of recurrent strokes, which constituted more than half the 
number of the cardiovascular events. Surprisingly, the 
presence of silent lacunes resulted in non-significant ad-
justed HRs of death below 1.0. As expected, the adjust-
ment for potential confounders resulted in lower esti-
mates compared to the crude HRs, and we observed that 
the effect of the adjustment was essentially driven by age. 
However, it is possible that these estimates were biased 
due to the effect of one or several residual confounders.
 We found that the prevalence of silent lacunes strong-
ly depended on age. This is in agreement with older stud-
ies on silent brain infarcts in stroke patients  [9] , and with 
population-based studies  [2] . Though it seems that silent 
lacunes, in part, could be a phenomenon of normal age-
ing, our age-adjusted analyses showed that multiple silent 
lacunes were associated with a 2.5-fold higher risk of re-
current ischemic stroke. Therefore, the finding of silent 
lacunes on brain imaging in stroke patients should be 
Table 3.  Rates per 100 person-years and Cox proportional hazard analysis of recurrent ischemic stroke, death, 
and cardiovascular events
Number of silent 
lacunes
Number Rate Crude HR (95% CI) Model 1: adjusted 
HR (95% CI)a
Model 2: adjusted 
HR (95% CI)b
Recurrent ischemic stroke
0 33 1.6 Reference Reference Reference
1 7 2.5 1.60 (0.71–3.62) 1.53 (0.67–3.49) 1.35 (0.58–3.11)
≥2 13 5.0 3.05 (1.61–5.81) 2.52 (1.25–5.09) 1.62 (0.74–3.55)
Death
0 56 2.6 Reference Reference Reference
1 7 2.4 0.92 (0.42–2.03) 0.56 (0.25–1.25) 0.49 (0.22–1.10)
≥2 13 4.4 1.68 (0.92–3.07) 0.65 (0.33–1.25) 0.52 (0.26–1.03)
Cardiovascular events
0 68 3.4 Reference Reference Reference
1 11 4.0 1.23 (0.65–2.32) 1.16 (0.61–2.22) 1.07 (0.55–2.06)
≥2 17 6.6 1.88 (1.11–3.21) 1.51 (0.86–2.66) 1.19 (0.64–2.23)
 Cardiovascular events represent the composite endpoint of stroke, TIA, myocardial infarction, or arterial 
thromboembolism. 
a Model 1: adjusted for age, sex, congestive heart failure, hypertension, diabetes, and vascular disease. 
b Model 2: additionally adjusted for white matter hyperintensities.
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considered an ominous sign, and should be considered in 
the prognostication and the counseling of the patient. 
Also, attention should be paid the potential cognitive 
consequences of silent lacunes. Neuropsychological dis-
turbances are common in patients with silent lacunes but 
may easily go unrecognized  [30] . At present, no evidence 
exists that ischemic stroke patients with silent lacunes 
should be treated differently.
 The main strengths of our study are the relatively large 
size of the cohort, the completeness of the follow-up, and 
the application of MRI for the assessment of silent lacu-
nes. There are also important limitations to consider. 
First, we did a registry-based study; thus, we cannot rule 
out misclassification of both the diagnosis of stroke and 
the comorbidities, but the validity of the Danish Stroke 
Registry is high. Second, we included only those patients 
who had done an MRI scan. Compared to the entire 
stroke cohort, these patients were younger and had minor 
strokes, and this selection may be a potential limitation to 
the generalizability of our findings. Third, MRI scans 
were rated only by a single stroke neurologist. Although 
a small validation sample was also rated by a consultant 
neuroradiologist and reproducibility was very high, we 
cannot rule out rater bias.
 In conclusion, multiple silent lacunes are associated 
with an increased risk of ischemic stroke recurrence in 
patients with incident ischemic stroke and no AF. The 
risk of death or cardiovascular events was not significant-
ly influenced by the presence of silent lacunes.
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